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Abstract 
 
Escherichia coli (E. coli) is part of the commensal microflora of the chicken intestinal 
tract, being commonly an opportunistic bacteria that causes disease in immunologic 
deprived chickens.  However, there are extra-intestinal E. coli strains, the avian 
pathogenic Escherichia coli (APEC) that are able to cause colibacillosis by itself, due to 
its invasive ability. The colibacillosis and colisepticemia are responsible for significant 
economic losses in poultry industries worldwide, mainly due to the low feed conversion  
rate with consequent weight loss, high cost of treatments during production, poor 
carcass quality with consequent rejection at slaughter and high mortalities rates. The 
increasing high patterns of antibiotic resistance acquired by these bacteria, as well as the 
restriction to the antibiotic usage implemented by the European Union, have encouraged 
the search of new solutions to control severe infections ensuring good meat quality and 
minimizing environmental impact.  
Bacteriophages (phages), virus infecting exclusively bacteria, have been proposed as 
valuable alternatives to antibiotics based on their capacity to infect and destroy the 
bacteria, releasing in few minutes progeny that will infect the surrounding hosts. 
The presented work aimed at developing an efficient, safe and competitive phage based 
product to control colibacillosis in poultry. The work encompassed five different stages: 
firstly, different bacteriophages active for a wide range of APEC strains were isolated 
and characterized; secondly, an in vivo evaluation of the toxicity of the phage 
suspensions were performed, thirdly the effect of the route of administration and phage 
titre on phage dissemination in the chickens’ organisms was assessed; fourthly  the 
efficacy of the phages presenting the wider lytic spectrum was evaluated through in vivo 
efficiency trials; finally, large animal trials were performed to validate the efficacy of 
the phage product.  
Phages were isolated from poultry sewage and tested against 148 O-serotyped APEC 
strains. The results showed that 70.5% of the tested strains were sensitive to a 
combination of three of the five isolated phages. Taxonomically, two of these three 
phages, phi F61E and phi F78E look like 16-19, T4-like phages (Myoviridae) and the 
other, phi F258E is a T1-like phage and belongs to the Syphoviridae family. All belong 
to the Caudovirales order. Restriction fragment length polymorphism (RFLP) patterns 
demonstrate that all phages were genetically different. The in vivo evaluation of the 
toxicity of the phage lysate revealed that the phage suspensions did not promote any 
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decrease in feed and water intake, or body weight lost during the in vivo trial and the 
post mortem necropsies did not show any macroscopic lesions in the internal organs. 
These observations supported that the lysate was not toxic for chickens.  
The in vivo assessment of the effect of the route of administration and the dosage in the 
dissemination of the phages in the chicken’s organs, revealed that when administered 
orally and by spray, all the phages reached the respiratory tract, as well as the 
bloodstream. Intramuscular administration enabled the phages to reach all chickens’ 
internal organs. Results suggested that, besides the intramuscular administration (not 
feasible to use in flocks), the oral and spray administration can be considered promising 
administration routes to treat respiratory E. coli infections in poultry.  
The in vivo evaluation of the efficacy of phi F78E to control severe E. coli infections 
revealed that phage performance is dosage dependant and only a high concentration of 
109 PFU/ml allowed a decrease in 25% and 43% in chickens’ mortality and morbidity, 
respectively. Interestingly, the phage cocktail (of phi F61E, phi F78E and phi F258E) 
administered in the water drinking and by spray in a single application, and composed 
by 5×107 PFU/ml of each bacteriophage, was able to control the mortality rate in 
naturally infected chicken flocks, refractive to antibiotherapy. The mortality felt from 
2.2% in average, to under 0.5% in no more than three weeks, with no recidivism.  
In conclusion, with this work it was possible to obtain an antimicrobial product, 
comprised by a combination of three different lytic phages, which demonstrated to be 
safe for chickens and efficient against colibacillosis in the poultry industry.  
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Sumário 
 
 A Escherichia coli (E. coli) é uma bactéria que integra a flora intestinal das aves, e que 
frequentemente se comporta como oportunista, causando doença em aves imuno-
deprimidas. Contudo, existem estirpes extra-intestinais patogénicas (APEC) que são 
capazes, pelas suas capacidades invasivas, de causar infecções (colibacilose) que podem 
degenerar em septicemias. Estas infecções são responsáveis por perdas económicas 
importantes na indústria avícola, devido a baixas taxas de conversão alimentar com 
consequentes perdas de peso das aves, elevados custos de tratamento na produção, baixa 
qualidade da carcaça que leva a rejeições no matadouro e elevadas taxas de mortalidade. 
O aumento do padrão de resistências a antibióticos adquiridos por estas bactérias, bem 
como as restrições que a Comunidade Europeia tem vindo a impor no uso destes anti-
microbianos, vem relançar a importância do desenvolvimento de alternativas 
terapêuticas. 
Os bacteriófagos (fagos), são vírus que parasitam exclusivamente bactérias e que têm 
vindo a surgir como alternativa valiosa à terapia tradicional. A sua capacidade de 
infectar e destruir bactérias hospedeiras, libertando nova geração com potencial para 
infectar os hospedeiros circundantes são características que corroboram a sua valia. 
O presente trabalho visou o desenvolvimento de um produto à base de fagos para o 
controlo de colibaciloses na indústria avícola, que se mostrasse eficiente e inócuo e que 
fosse competitivo. O trabalho compreendeu cinco fases diferentes: em primeiro lugar, 
bacteriófagos distintos que infectavam uma vasta gama de estirpes APEC foram 
isolados e caracterizados; seguidamente, foi efectuada a avaliação in vivo da toxicidade 
da suspensão de fagos; em terceiro lugar, foi testada a influência da via de 
administração e da concentração de fagos na sua disseminação no organismo das aves; 
posteriormente a eficiência dos fagos com o espectro de lise mais amplo foi avaliada, 
através de experimentação in vivo; finalmente foram realizadas experiências em aviários 
experimentais para validar a eficácia do produto à base de fagos.  
Os fagos foram isolados de camas de aviários e testados para 148 APEC serotipadas 
para o antigénio “O”. Destas, 70.5% revelaram-se sensíveis a pelo menos um de três dos 
fagos. Taxonomicamente, todos os fagos se inserem na ordem dos Caudovirales, sendo 
que dois deles, o phi F61E e o phi F78E são fagos 16-19, do tipo T4 (Myoviridae) e o 
outro, phi F258E é um fago do tipo T1 (Syphoviridae). Padrões de RFLP demonstraram 
que todos os fagos são geneticamente diferentes.  
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A avaliação in vivo da toxicidade do lisado de fagos revelou que a suspensão de fagos 
não provocou qualquer diminuição na ingestão de alimento e água nem perda de peso, e 
a avaliação post mortem das carcaças não revelou lesões macroscópicas nos órgãos. 
Estas observações corroboram a inocuidade do produto, para as aves.  
As experiências in vivo para analisar o efeito da via de administração e da concentração 
da suspensão, na disseminação dos fagos no organismo das aves, indicou que quando 
administrados por via oral e por spray, qualquer dos tipos de fago em teste atingiram o 
tracto respiratório e a corrente sanguínea. A administração intra-muscular, permitiu que 
os fagos testados fossem recuperados em todos os órgãos analisados. Os resultados 
sugerem que, para além da administração intramuscular (modo que não é prático para o 
maneio em bandos), a administração oral e nasal deverão ser veículos eficientes de 
transporte de fagos para o tratamento de infecções respiratórias por E. coli em aves. 
A avaliação in vivo da eficiência do phi F78E para o controlo de infecções severas de E. 
coli, revelou que o desempenho do fago estava dependente da dose, e que apenas uma 
concentração elevada, de 109 PFU/ml, permitiu um decréscimo na mortalidade e 
morbilidade das aves, respectivamente de 25% e 43% em média.  
Curiosamente, a combinação de fagos (phi F61E, phi F78E e phi F258E), numa 
concentração de 5×107 PFU/ml cada um, administrado na água de bebida e por spray 
numa única aplicação, foi eficiente no controlo da mortalidade em bandos naturalmente 
infectados por APEC, e em que os antibióticos não tinham tido sucesso terapêutico. A 
mortalidade desceu, em média, de 2.2% para valores inferiores a 0.5% em não mais de 3 
semanas, sem recidivas. Em conclusão, este trabalho possibilitou o desenvolvimento de 
um produto constituído por três fagos, que demonstrou ser inócuo e eficiente no 
controlo de colibacilose na indústria avícola. 
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Outline of the thesis  
 
This thesis is structured in 7 chapters: 
Chapter I presents the background information about the role of Escherichia coli (E. 
coli) in the poultry industry, the motivations of finding new alternatives to antibiotics, 
and the features and research studies that support bacteriophages’ therapeutic potential. 
In Chapter II, the selection and characterization of bacteriophages (phages) to be 
incorporated in a therapeutic cocktail, aiming at controlling pathogenic E. coli strains in 
poultry is described. The results presented in this chapter comprise the isolation of 
phages from poultry sewage, the in vitro evaluation of phages lytic spectra towards a 
panel of isolated and O-serotyped APEC strains, the phages morphological 
characterization by Transmission Electronic Microscopy (TEM), the phages life cycle 
investigation by the induction of infected hosts with Mytomicin C and the genetic 
comparison between phages’ DNA, performed by restriction fragment length 
polymorphism (RFLP) patterns.  
Chapter III addresses the in vivo toxicity evaluation of the cocktail composed by the 
three selected phages, phi F78E (Myoviridae), phi F258E (Syphoviridae), and phi F61E 
(Myoviridae). 
The results of the influence of the administration route and the phage dosage in the 
dissemination of the three selected phages in the chickens’ organs are presented in 
Chapter IV. 
In Chapter V are reported the results of confined experiments intending the in vivo 
phage performance evaluation on treating severe respiratory E. coli infections in 
chickens, when administered orally and by spray.  
Naturally E. coli infected chicken flocks refractive to antibiotherapy, were used in the 
work described in Chapter VI, to perform large scale experiments with the three-
phages cocktail, composed by phi F61E, phi F78E and phi F258E.  
Chapter VII encloses final conclusions as well as suggestions for future works. 
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1. COLIBACILLOSIS IN POULTRY INDUSTRY 
 
1.1  Escherichia coli 
Escherichia coli (E. coli) is a Gram-negative bacillus, facultative anaerobic and non-
sporulating bacteria that belongs to the family of Enterobacteriaceae. Its optimal 
growth occurs at 37 °C. The cells are about 2-3 micrometres (μm) long and 0.5 μm in 
diameter. Some strains have multiple “flagells” around the cell to confer motility, and 
fimbria or adesins that allow its attachment to the intestine walls. These bacteria are 
normal inhabitants of the intestinal lumen of humans and other warm-blooded animals 
21. As in all Gram-negative bacteria, the outer surface membrane of the cell wall is 
constituted by  complexes of lipopolysaccharides (LPS), macromolecules responsible 
for several of the bacteria biological properties 126. These chemical structures, also 
known as endotoxins, comprise three regions or domains: the lipid A, hydrophobic, is 
projected into the outer membrane, conferring greater stability and resistance;  an 
intermediate glycosidic part consisting of a linear and hydrophilic region of 
polysaccharides, and a third region, named O-chain, with repetitive subunits of 
monosaccharides responsible for much of the immunospecificity of the bacterial cell 17. 
The number of the O-chain subunits defines the bacteria O-serotype, a factor 
conditioning virulence on Gram-negative bacteria 65. 
E. coli possess the ability to transfer DNA via bacterial conjugation (through plasmids 
exchange), by transduction (carried by a bacteriophage), or by transformation (acquired 
from the environment as “naked” DNA). These processes allow genetic material to 
spread horizontally through an existing population and might led to transfer genes 
encoding advantageous proteins, or conversely toxins, from one bacteria to another 13. 
 
 
1.2 E. coli role in poultry industry 
 
Escherichia coli is part of the commensal microflora of the chicken intestinal tract. 
Particularly in chickens and turkeys’ intestines, it can reach concentrations of 106 
CFU/g of fecal material 7, and are found in several fecal contaminated places, like 
water, dust, feathers, skin, etc. 50. Under certain conditions, E. coli infections can arise 
causing colibacillosis. The most important source of transmission seems, thus, to be 
fecal contamination through the inhalation of the microorganisms into the respiratory 
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tract 8. The oxygen exchange zones, in this case lungs and air sacs, are very vulnerable 
to bacteria incursion and subsequent multiplication. Avian air sacs have no resident 
cellular defense mechanisms and must rely on an inflammatory influx of heterophils 
(highly phagocytic granulated leukocytes) as the first line of cellular defense, followed 
by macrophages 86. 
Commonly, E. coli is an opportunistic bacteria that causes disease in immunologic 
deprived chickens. Stressful external agents, as other bacteria or virus infections 
affecting respiratory system (Mycoplasma gallisepticum, infectious bronchitis virus 
(IBV), Newcastle disease virus (NDV)), or adverse environmental conditions (as 
temperature, and humidity, high concentrations of ammonia and dust in poultry houses)) 
frequently contribute to decrease chicken immunologic defenses 24.  However, some E. 
coli strains, named avian pathogenic Escherichia coli (APEC), are able to cause 
colibacillosis by itself, due to its invasive ability (Figure I.1 A). These strains belong to 
an extra-intestinal pathogenic group, and possess specific virulence traits that are 
determinant for the host infection and to development of septicemia. Many adhesins 
promoting the attachment of the bacteria to cell receptors are encoded: type 1 fimbriae 
have been involved with the initial stages of the upper respiratory colonization, whereas 
the P fimbriae are involved in colonization of the internal organs 66. Other virulence 
factors known to be associated with APEC, include the presence of the K1 antigen, 
particularly when associated with O1 and O2 serogroups, the ability to secrete 
aerobactin, the temperature-sensitivity of the hemagglutinin (Tsh),  serum resistance, 
the presence of some  pathogen-specific chromosomal regions, and others 23, 24, 28, 86. 
Respecting to the O-serotype in poultry, 10 to 15% are pathogenic 56 and belong to 
specific O-serogroups, as O1, O2, O5, O8, O15 and O78 24, 133, 25, 52, 77.  
The pathogenesis of the infection comprises the colonization of the respiratory tract by 
the bacteria, the passage through the epithelium and the penetration into the mucosa of 
the respiratory organs. The survival and multiplication of the bacteria in the blood 
stream, leads consequently to septicemia that degenerates in multiple organ lesions, 
typically pericarditis, aerosacculitis, perihepatitis and peritonitis (Figure I.1 B) 49. In vivo 
experiments showed that, although APEC cells were effectively rescued from blood by 
macrophages, others were found to be occasionally free in the airways, as the air sac 
lumen, in interstitial tissues of infected chickens, and also mixed with heterophils, 
erythrocytes, and fibrin 100. 
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type) with the administration of this drugs, and so are able to multiply and become 
dominant 66, 67, 100. These mechanisms result in an unavoidable loss of the efficacy of 
treatments of the most commonly used active ingredients, in poultry industry.  
The birds’ pathogenic bacteria serotypes, have a high capacity of dispersion among 
successive flocks in the same aviary, being thus the most frequently exposed to 
antibiotics 56, 20, 57, 122, 123.  
Despite the indubitably losses in poultry industry, other concerns arise from microbial 
resistances. In fact, the disrespect for the safety interval between the antibiotic 
administration and slaughter, might became an important clinical and public health 
problem 20, 61, 73.  
World Health and Life Science organizations are concerned about the deleterious effects 
that antimicrobial resistant bacteria ingested from animal derived food products may 
have on human health, like increased duration of illness, treatment failure, and loss of 
therapeutic options 26, 123. FDA has also emitted reports commenting this problem and 
suggesting the application of alternative methods for the control of pathogenic microbes 
29, 30 .  
From the environmental point of view, effluents containing antibiotic residues can 
create a reservoir of resistance microorganisms on soil and water. Those substances can 
persist in the environment for long periods of time after treatment, affecting the 
microbial community as long as they remain intact and at growth inhibitory levels 72, 90.  
 
3. BACTERIOPHAGES 
 
3.1 Structure and life cycle 
 
Bacterial viruses or bacteriophages (phages), are likely to be the most widely distributed 
and diverse entities in the biosphere. Phages infect exclusively bacteria and are 
associated with almost all bacterial genera, including cyanobacteria, archaebacteria and 
mycoplasms. These virus may be grouped on the basis of a few general characteristics 
including the host range and strategies of infection, the morphology and particle size, 
the nucleic acid, the molecular weight and the genome sequence, the morphogenesis, 
the phylogeny, the sensitivity to physical and chemical agents, among others 55. 
Bacteriophages are composed of protein or lipoprotein capsids, which are 
morphologically heterogeneous, ranging from polyhedral (like hexagonal) structures, to 
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filamentous or to pleomorphic (for example spherical) structures. The capsid, enclose 
the phage nucleic acid, DNA or RNA, that can be arranged as linear (free extremities) 
or circular molecules, and in single (ss) or double (ds) strains. Some phages have small 
genomes (few encoding 12 or fewer genes) and other have large genomes that can reach 
480 000 base pairs (bp) 27, 51, 55, 92. The advent of the electron microscope allowed phage 
biologists to measure the size of phage structures and to determine the symmetry of the 
capsid, giving rise to a taxonomy based on morphotypes (Table I.1) 92. Phages with a 
polyhedral capsid often carry a more or less complex tail (Caudovirales order), to which 
a base plate, spikes, or tail fibers can be attached. Those are specific connecting 
structures ensuring the contact of the phage with the receptors of the host cell wall. The 
tails can be contractile (Myoviridae family), long and non-contractile (Siphoviridae 
family) or short and non-contractile (Podoviridae family) 27, 51, 92.  
 
Table I.1 Classification of phages according to the International Committee on 
Taxonomy of Viruses (ICTV) 84 
Order Family Morphology Nucleic acid 
Caudovirales Myoviridaea Non-enveloped, contractile tail Linear dsDNA 
 Siphoviridaea Non-enveloped, long non-contractile tail Linear dsDNA 
 Podoviridaea Non-enveloped, short non-contractile tail Linear dsDNA 
 Tectiviridaeb Non-enveloped, isometric Linear dsDNA 
 Corticoviridaeb Non-enveloped, isometric Circular dsDNA 
 Lipothrixviridae Enveloped, rod-shaped Linear dsDNA 
 Plasmaviridae Enveloped, pleomorphic Circular dsDNA 
 Rudiviridae Non-enveloped, rod-shaped Linear dsDNA 
 Fuselloviridae Non-enveloped, lemon-shaped Circular dsDNA 
 Inoviridae Non-enveloped, filamentous Circular ssDNA 
 Microviridae Non-enveloped, isometric Circular ssDNA 
 Leviviridae Non-enveloped, isometric Linear ssRNA 
 Cystoviridaeb Enveloped, spherical Segmented dsRNA 
aTailed phages 
bLipid containing 
 
Phage receptor sites are located on different parts of bacteria, and include structures 
such as proteins, lypopolyssacharides or sugars, anchored to the cell membrane or as 
part of the cell wall structure. Some of them are present permanently on the cell while 
others, as for example the fertility (sex) fimbriae, are produced only by bacteria in the 
logarithmic growth phase 27,55.  
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known as a prophage, and remain incorporated either into the bacteria chromosome or 
existing as an extra chromosomal plasmid 45, 71.    
 
Figure I.3 Phage lytic and lysogenic cycles: main processes (adapted from: 
http://faculty.irsc.edu/FACULTY/TFischer/micro%20resources.htm). 
Conversely, virulent phages are encouraged to be used in therapy, based on their 
capacity to infect and destroy the bacteria, releasing in few minutes progeny that will 
infect the surrounding hosts. Briefly, the cells infection mainly comprises the adsorption 
and the irreversible attachment of the phage to the bacteria. These processes allow 
phages to get through the bacterial membrane and to inject the nucleic acid through it. 
The adsorption is mediated by the phage tail fibers from the base plate or by some 
analogous structure, depending on the phage taxonomy. These structures attach to 
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specific receptors on the bacteria (LPS, pili, lipoprotein, …). The nucleic acid from 
capsids is transferred into the bacterial cell by different mechanisms, according to the 
phage type. In subsequent steps, the viral genome is transcribed using the host 
metabolic equipment - aminoacids, nucleotides, ribosome, enzymes - beginning its 
translation on the phage structural components and on genetic material. Particles 
organize themselves in the intracellular space to be released as infectious viral particles 
45, 82. Some phage strategies are known to promote the host lysis. All the dsDNA encode 
in its genome a hydrolytic enzyme, named lysine, which degrade the cell wall 
components, the peptidoglycan or murein. To carry on this feature, this enzyme needs 
another protein, the holin, also encoded by phage genome sequences 132. Holins act 
forming “holes” in the membrane. Those formations allow lysine, stored in the 
cytoplasm, to reach the peptidoglycan layer and to disaggregate this structure, and the 
phages produced during the infection are released 107. In dsDNA type phages, the holin 
is the factor that controls the lysis moment 127, 132. A holin inhibitor also encoded by the 
phage, indicate the finalization of the lysis process. On the other hand, ssDNA and 
ssRNA phages have single and specific genes for the host lysis. No enzyme capable of 
degrading the peptidoglycan structure was found in lysates of these phage types, and the 
genetic analysis suggests no genes encoding those proteins. The lytic activity may occur 
after phages replication and morphogenesis. Lyses seems to be a secondary activity of 
structural proteins 124, 132. 
 
3.2 Phage therapy 
 
Many reviews and reports have been published, focusing the problem of bacterial 
antibiotic resistance, discouraging  the use and abuse of antimicrobials in food animal 
production, and challenging  the scientific community to find feasible alternatives of 
reducing microbial pathogens loads 3, 29, 128.  
The evidences of bacteriophage advantages over common therapies have been 
triggering numerous research works aiming the characterization and evaluation of 
phages as safe and efficient antimicrobial particles.  
One of the phages characteristics supporting its therapeutic use is their exclusivity on 
prokaryotic infection, being metabolically inert in their extracellular form.  
Accordingly, phages cannot interact with humans, animals or plants cells, having 
therefore a highly encouraging safety profile 51. The idea of phages harmlessness to 
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human and animals’ health is reinforced, taking in account its ubiquity in Nature. 
Indeed, phages are the most-numerous life form on earth, and phage population in the 
biosphere is calculated to be around 1031 phages, existing 1010 phages per liter of surface 
seawater 78 and 107 to 109 per g of sediment or topsoil 105, 4, 5, 52, 131.  Thus, it is 
reasonable to say that phages are regularly consumed in food and usually colonize the 
intestine 19, 47. Additionally, another important characteristic sustaining the phages use 
for therapy is their high specificity for a given host, targeting and recognizing specific 
receptors in the bacteria. This trait avoids the indiscriminate lysis of the normal 
microflora, contributing in consequence to preserve the microbial balance. This assumes 
high importance in therapy since patients may be more protected against secondary 
infections 85. Other advantage on using phages for treatments relies on its exponential 
growth following the host infections. If this event takes place on critical infection sites, 
it might allow phages to exert a broader therapeutic action to control illness. The phages 
ability to infect antibiotic resistant bacteria, overcoming resistance problems and the 
low cost of phage production are other factors supporting its use. Besides all these 
properties associated with bacteriophages, they sill enclose a great potential to be 
genetically manipulated in order to improve their efficiency 61.  
In the last two decades, phage therapy applied to control infections rising from animal 
production industries gained special attention. In veterinary Medicine, several studies 
have already established “the proof of principle” of the phage therapy. For example, 
researchers of the Institute for Animal Disease Research, in the UK, reported successes 
on the use of phages in experimental treatments of E. coli infections in mice113 and in 
infections of diarrhea-causing E. coli strains in the alimentary tract of calves, lambs, and 
piglets 114-116. Barrow et al. (1998) 9, reported the successful use of phages in  
preventing septicemia and a meningitis-like infection in chickens, also caused by E. 
coli. Similar studies with encouraging results were reported for mice and guinea pigs 
infected with  Pseudomonas aeruginosa and Acinetobacter 117-119, Klebsiella ozaenae, 
Klebsiella rhinoscleromatis scleromatis and Klebsiella pneumonia 10, 11. 
More recently, Cerveny et al. (2002) 18 confirmed the therapeutic potential of 
bacteriophages as therapeutic agents against V. vulnificus in a mouse model. Park et al. 
(2003) 93 treated water-borne infection of Pseudomonas plecoglossicida in fish by 
impregnating phages in the feed. Ronda et al. (2003) 106 confirmed the therapeutic 
phage activity against Streptococcus pneumoniae also in fish. Sklar and Joeger (2001) 
111, Fiorentin et al. (2004) 32 and Atterbury et al. (2007) 6 designed experiments for 
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reducing Salmonella colonization in poultry intestine, obtaining  satisfactory results. 
Huff and co-authors have been reaching successful results in treating colibacillosis in 
chickens 58-64. 
In Human Medicine, the safety and effectiveness in the use of phages for therapeutic 
purposes was demonstrated by Bruttin and Brussow (2005) 14 in a  phage safety test run 
in healthy adult volunteers received in their drinking water a low dose of the well 
described  T4 phage. No adverse events related to phage application were reported.   
Nevertheless, despite all favorable reports, phages are still matter of controversy. One of 
the drawbacks of phage therapy is the arising of phage resistant bacteria. Mechanisms 
against phage infection might be developed by the host bacteria, and two main problems 
might come up: a negative influence in phage therapy efficacy as well as the mutants’ 
propagation in the environment. In general, naturally occurring mechanisms of phage 
resistance, include mutations at the bacteria DNA level that allows the accomplishment 
of several defense resources: the prevention of phage infection by altering the cell 
surface carbohydrates that act as phage receptors, the blocking of phage adsorption or 
penetration systems, or the abortion of infections 46. Considering that the surface 
component associated with bacterial virulence also seems to be the receptor for many 
phages attachment, there are evidences that bacteria resistant to phages usually present 
an attenuated virulence 9, 88, 95, 109, 113, 114. Following this idea, Barrow et al. (1998) 9 state 
that the use of phages attaching to structures that are essential for virulence, such as, for 
example, the K1 antigen, may minimize the necessity of finding solutions to destroy 
resistant bacteria. In this particular case, most phage-resistant mutants that arise would 
be K1 negative, and thus less virulent. According to the same authors, this adaptation 
may contribute for successful phage therapy or control. 
Other strategies might be carried out by phages, to evolve in the same sense as bacteria. 
These viral particles are also able to suffer mutations, some of which may overcome 
bacteria resistance 47, 81, 87. 
A good strategy to overwhelm the phage resistant problem is to include in the 
therapeutic cocktail of phages with different bacterial receptors, which might delay the 
appearance of resistances, and on the other hand, broaden the therapeutic applicability 
of the product 18, 68. In addition, when phage-resistance occurs, it should be possible to 
rapidly select a new phage active against the phage-resistant bacteria.  
Another limitation being pointed out to phages is their narrow host range, if they are 
strain-specific rather than species-specific. Due to the high diversity of bacterial variants 
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to control, this characteristic could lead to some difficulties on preparing phage products 
and its therapeutic action might be restricted. Again, the usage of a cocktail of phages, 
including preferentially polyvalent phages (which are phages that can infect multiple 
species) can be a way to enlarge the lytic spectra and at the same instance delaying the 
resistance occurrence 15, 51, 61, 85, 112, 115, 120.   
The development of phage-neutralizing antibodies is another potential problem which 
may obstruct phage effectiveness on treating recurrent infections in vivo. The prior 
exposure of a pathogen to this antimicrobial is likely to accelerate an immune reaction 
to therapeutic phage 54, 68, 88, 120.  In fact, the development of neutralizing antibodies after 
parenteral administration of phages has been well documented 67, 115. It is indeed unclear 
how significant this problem may be for phage therapy, especially when phages are 
administered orally or locally 83. According to Sulakvelidze (2001) 120, theoretically, the 
development of neutralizing antibodies should not be a significant obstacle during the 
initial treatment of acute infections, once the kinetics of phage action is much faster 
than the production of neutralizing antibodies by an organism. Furthermore, it is not 
clear how long the antibodies will remain in circulation and of which variables this 
depends. Thus, further studies are advised to be conducted to certify the validity of this 
concern120.  
Relatively to phages safety, there is also some apprehension on administering the phage 
lysate as a therapeutic product, without removing the host debris. As phage infection 
culminates on the bacteria disruption, the cell wall components are consequently 
released into the environment as cell debris. In Gram-negative bacteria lysates, also 
endotoxins (LPS) are released. Those structures easily pass through filters (0.22 μm) 
commonly used to remove the whole bacteria from phage suspensions (Williams, 
2001b).  The presence of these endotoxins in the lysates can lead to undesired side 
effects on phage therapy. The LPS toxicity is associated with the lipidic component of 
the molecule, the lipid A, while the immunogenicity is associated with the O-chain 
polysaccharide component, the O-antigen 12, 22, 101, 121, 129.  
If it is true that small amounts of endotoxins can be advantageous for an organism, 
activating defense mechanisms to face infections, it must be said that, in larger amounts, 
these macromolecules may induce a variety of inflammatory responses being often part 
of the pathology of Gram-negative bacterial infections. Although individuals vary in 
their susceptibility to endotoxins, the sequence of pathophysiological reactions follows 
a general pattern: a latent period followed by physiological distress. Immunologic and 
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neurological system activation, induction of blood coagulation, general metabolic 
harmful effects, alteration of blood cell populations, pyrogenicity (fever induction), 
hypotension, hepatotoxicity, tissues necrosis and in more serious cases, endotoxic shock 
and death, are some of the known reactions to an endotoxin parenteral challenge 22, 130. 
Some processes are being used to isolate phages from crude lysates, in order to get 
suspensions free of LPS. The density gradient ultracentrifugation (ex. cesium chloride  
gradients) 47, the ultrafiltration followed by size exclusion chromatography 12, specific 
“ready-to-use” column’ systems based on affinity chromatography 102 are some of those 
processes, and are easily adaptable to phage small scale production. However, it 
becomes more difficult and less feasible to implement the existing solutions in larger 
scales, as required for the industry supply. It is thus important to adapt the purification 
level of these kinds of suspensions, to the purpose of the therapeutic product and to the 
variables of the therapeutic intervention. This includes, for example, the target specie 
(according to Culbertson and Osburn (1980) 22, there is a variable sensitivity to 
endotoxin among species, for example, chickens are more resistant to endotoxins effects 
compared to mammals) and the administration route (the oral or the spray 
administration of crude phage lysate shall have different approaches in terms of 
endotoxins effects on live organisms, comparing to the intramuscular or parenteral 
administration).  
 
3.3 Motivations and expectations arising from bacteriophage technology 
 
Scientific research groups have been improving the existing technology based on 
bacteriophages, and developing new approaches. Since the phage therapy successes and 
setbacks of the experiments in the former Soviet Union 15, 120, phages have been an 
object of interest. Several steps forward, even in an adverse epoch for phages due to the 
antibiotics rising, allowed the knowledge consolidation and the recognition of the 
research needs in this area. The trust on phages’ high potential allowed a renewed hope 
for its use as antimicrobials tools, and the necessity to demystify those virus basic 
principles and mechanisms of action in order to get a better perception of phage 
Biology, consequently arise. The evolution of the knowledge on the phage Phylogeny, 
by describing statistically the similar 
ity or differences between groups of species with an evolutionary tree, largely 
contributed for this intend. In another perspective, the phages genetic characterization 
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allowed the disclosure of the several protein functions. Indeed, the growth of interest in 
bacteriophage coincides with recent advances in Molecular Biology technologies. Since 
the 1980s the number of catalogued sequenced genomes maintained by the National 
Center for Biological Information (NCBI) has grown exponentially. From 2002 until 
now, the number of known phages grew from around 100 80 to approximately 520 91. 
New phage applications emerged, and new generation phage products are being 
suggested 70. Answers from fundamental research and proposals from applied 
investigation, consolidated important phage applications and drew attention to new 
ones. In fact, phage technology has been applied to a wide range of fields, as food 
safety, environmental technology, human and veterinary Medicine, Biotechnology, 
Immunology, Epidemiology, among others 15, 120. Indeed, phages might play important 
roles, as the reduction of cross-contaminations through direct applications of 
bacteriophages or its enzymes in surfaces, manipulated food 16 or carcasses after 
slaughter 74; the bio-recognition of bacterial pathogens as specific antigen molecules in 
diagnosis 77, 89; its use as tracers, indicators of pollution or in the monitoring and 
validation of biological filters in the environment 81; the treatment or control of bacterial 
infections in animals or humans 120; the vaccination using phages as delivery vehicles of 
the antigen in the form of  protein or DNA 104; the development of laboratory techniques 
as protein/antibody library screening tools, like  phage display or phage immobilization 
81, etc.. Genetically engineering bacteriophages offers great possibilities to developed 
the above described applications and to enhance phage technology approaches 70.  
From another perspective, phages present a continuous challenge for the fermentation 
industry in particular, dairy industry, where phage infections of bacterial stocks can be 
commercially disastrous 81.  
In parallel to studies of phage Biology and biotechnological applications, mathematical 
models are being developed to facilitate a better understanding of how to improve phage 
value 69, 97-99. 
Another interesting phage-based therapeutic advance, is centered in the use of phage-
encoded enzymes, produced actively during the lytic cycle, which destroy the bacteria 
cell wall from the interior of the infected cell and enable the release of the phage 
progeny 106,96.  In 1995, Vincent Fischetti designated those substances as “enzibiotics”. 
Several patents arise from Fischetti and colleagues research on enzibiotics aiming 
practical applications 34-44, claiming, among others, the development of products 
containing phage lytic enzymes in chewing gums, eye drops, nasal sprays, vaginal 
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suppositories and tampons, oral syrups or bandages. The use of lytic enzymes purified 
from phage lysate as important tools in bacterial destruction have also been reported in 
several studies 33, 47, 48, 75, 76, 79, 93, 110.  
The great diversity of phage technological applications and the added value of certain 
phage products is being the driving force of the creation of phage companies and the 
increase in research in this area. As examples, companies focused on the development, 
production and marketing of phage-based products might be mentioned: OmniLytics, 
Inc. (www.phage.com), EBI - Food Safety (www.ebifoodsafety.com), Biophage 
Pharma, Inc. (www.biophagepharma.net), Intralytix, Inc. (www. intralytix.com), Phage 
Biotech, Ltd. (www.phage-biotech.com), D&D Pharma (www.bakteriophag.com), 
Novolytics Ltd. (www.novolytics.co.uk), Controlvet, Segurança Alimentar 
(www.controlvet.pt), among many others. 
 
3.4 Legislation for phages use 
 
The use of phage as therapeutic agents in humans or animals still encounters a massive 
problem: the void in legislation. It is urgent to include in regulations, a specific edge for 
phages, avoiding the subjectivity of criteria that arises on adapting the inclusion of 
phage products on existing documents designed for other substances. Rigorous 
requirements for phage isolation, selection, characterization and production must be 
described as well as procedures for products validation. The knowledge of the 
bacteriophage Genetics and Ecology, might simplify the legislators task on defining 
procedures to guarantee phage safety control. Presently in EU, the phage 
commercialization approval is under criteria of already available legislation for other 
bio control substances, somewhat consistent with phages. Each member state has 
competencies to evaluate if the substances under approval are able to be commercialised 
and registered. For example, the Directive 98/8/CE of 16 February 1 establishes rules 
and procedures relative to the commercialisation of biocides and includes the viruses in 
the definition of “microrganism”. However, needs of new regulations are being 
recognised by the European Union. The regulation (EC) No 726/2004 of the European 
Parliament and of the Council of 31 March 2004 2 set up Community procedures for the 
authorization and supervision of medicinal products for human and veterinary use and 
establishes a European Medicines agency. This agency will implement EC procedures 
regarding the commercialization of high-technology medicinal products, particularly 
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that resultant from Biotechnology research, aiming the maintenance of the high level of 
scientific evaluation in the EU and thus the preservation of the confidence of patients 
and medical professionals. This regulation specifies the importance of these measures 
for new therapies lacking legislation. However the term “bacteriophage” is never 
mentioned. 
 In 2006, the Food and Drug Administration (FDA) and the United States Department of 
Agriculture (USDA) approved a phage-based product to control Listeria in food 
products, the LISTEX P100™ (from EBI - Food Safety), conferring the GRAS 
(Generally Recognized As Safe) status to the product, and thus allowing its use in food 
in the US. SKAL, the designated Public Inspection Authority of The Netherlands, 
confirmed that in conformity with EU Regulation (EEC) nr. 2092/91, Annex VI, 
Section B, LISTEX™ had the “organic” status that, under EU law, allowed the product 
to be used in the EU in regular and organic products. 
With regard to the Human Medicine, the entity that decides the marketing procedures 
for medicines in the EU is the Committee for Medicinal Products for Human Use 
(CHMP). CHMP is responsible for preparing the European Medicines Agency's 
opinions on all questions concerning medicinal products for human use, in accordance 
with Regulation (EC) No 726/2004. However, and citing Verbeke et al. (2007) 125, this 
Committee was established having classical drug products in mind, and the possibility 
to instigate the clinical studies that are required to generate the data demonstrating 
safety and efficacy of phage therapy, in the actual regulatory settings, will be very 
difficult or even impossible.  
European regulation defines a medicinal product as ‘any substance presented for 
treating or preventing disease in human beings’. According to this definition, from a 
therapeutic point of view, bacteriophages are medicinal products. However, researchers 
are not being able to document bacteriophages as such, once they cannot fulfill all the 
requirements to do clinical trials in humans (national notification, Eudract number, 
production license etc.).   
In Poland, bacteriophages are already being used therapeutically. In the L. Hirszfeld 
Institute of Immunology and Experimental Therapy from The Polish Academy of 
Sciences, patients infected with antibiotic-resistant bacteria, can be treated with phages 
53. The regulatory basis for this therapeutic use on patients is the Declaration of 
Helsinki. In the Paragraph 32 of this Declaration, is stated: 
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“In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic 
methods do not exist or have been ineffective, the physician, with informed consent from 
the patient, must be free to use unproven or new prophylactic, diagnostic and 
therapeutic measures. (…) these measures should be made the object of research, 
designed to evaluate their safety and efficacy (…) information should be recorded and, 
where appropriate, published”. 
However, the Declaration of Helsinki is only applicable when other therapeutic methods 
are not effective and thus is not a steady solution for phage therapy. As a long-term 
solution, it would be therefore vital the creation of a specific section for phage therapy 
under the Advanced Therapy Medicinal Product Regulation. 
 
 “We look forward to a time when phages, as both bacteria identifiers and biocontrol 
agents, are as ubiquitous in the clinic, on the farm, and even in the factory as Felix 
d’Herrele, over 85 years ago, so confidently hoped that one day they might be” 
(Goodrige and Abedon, 2003) 51.  
 
Shall we believe that this time has just begun?  
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1. INTRODUCTION 
 
Escherichia coli (E. coli) is present in the normal microflora of the intestinal tract of 
chickens. However, some of these E. coli strains are able to cause disease under certain 
conditions, like abnormal predominance over the other gut flora, host depressed 
immune system or adverse environmental exposure. Extra-intestinal pathogenic E. coli, 
termed avian pathogenic E. coli (APEC) possess specific virulence attributes causing 
invasive infections in poultry (chickens and turkeys), namely colibacillosis 48. The 
pathogenesis of APEC infections include the colonization of the respiratory tract, the 
crossing of the epithelium and penetration into the mucosa of the respiratory organs, the 
survival and multiplication in the blood stream and in the internal organs, and the 
production of adverse effects and lesions in cells and tissues 16. These bacteria can be 
typed according to the somatic cell-wall antigen (O-antigen), or the flagella antigen (H-
antigen). In poultry, 10 to 15% of the serotypes are pathogenic, and are present in the 
poultry environment causing a variety of disease syndromes including colibacillosis 5.  
 Avian colibacillosis is a complex syndrome characterized by multiple organ lesions, 
typically pericarditis, aerosacculitis, perihepatitis and peritonitis, and in its acute form 
degenerates in septicaemia. The consequent chickens’ high mortality rates and carcass 
rejection at slaughter causes significant economic losses in the poultry industry 
worldwide 14, 17. The most important source of transmission seems to be faecal 
contamination through the inhalation of the microrganism into the respiratory tract 5. 
E. coli isolates from poultry are frequently resistant to multiple drugs 29, 30. An increased 
concern over the consequences of the mechanisms that bacteria have developed, to 
prevent the inhibitory effects of the antibiotics in the treatment of animal bacterial 
infections is widespread 25, 36. The antibiotic capacity to select and allow proliferation of 
resistant bacteria is an important clinical problem with public health consequences. 
Antibiotic residues can be found in the environment for long periods of time after 
treatment 30. These active ingredients affect the microbial community as long as they 
remain intact and at growth inhibitory levels 29.  
World Health and Life Science institutions are concerned about a range of deleterious 
effects that antimicrobial resistant bacteria may have on human health, like increased 
duration of illness, treatment failure, and loss of therapeutic options as a consequence of 
human exposure to resistant bacteria through ingestion of animal derived food products. 
There have been three comprehensive reviews and reports on the problem of bacterial 
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antibiotic resistance, each of which comments on the use and abuse of antimicrobials in 
food animal production, and recommends application of alternative methods of reducing 
microbial pathogens loads 18, 26, 46. Also in animal production, there is serious 
consideration being given to restrictions on the use of antibiotics 19. 
Phage therapy is presented as an alternative to antimicrobial therapies. Bacteriophages 
or phages are viruses that exclusively infect bacterial cells. If they are obligate lytic 
phages, or virulent phages, multiply in the host bacteria and lyse it at the end of the 
cycle, after immediate replication of new phage particles. As soon as the cell is 
destroyed, the new phages can find new hosts. Like all viruses, phages are metabolically 
inert in their extra cellular form. These structures are only able to self-reproduce as long 
as the host bacteria is present, and thus are not toxic to non specific bacteria, animals or 
plants. In fact, their replication depends exclusively on the infection of a specific 
bacterial host and on the utilization of the host intracellular machinery to translate their 
own genetic code.  Phages are part of both gastrointestinal and environmental 
ecosystems and are among the simplest and most abundant organisms on earth 13, 43. 
Lytic phages are suitable for phage therapy in opposition to temperate phages. The 
former do not include the integrase genes on their genome, they lack the molecular basis 
for coexistence with the host and the potentiality to carry harmful genes from one host 
to another 11, 27, 38.  
Recently, well-controlled animal models have demonstrated that phages can rescue 
animals (chickens, mice, calves, pigs, lambs, fishes,…) from a variety of harmful 
infections, like E. coli or Salmonella infections 6, 8, 10, 23, 24, 33, 37, 40-42. 
In this study, in vitro efficiency of five phages was evaluated based on lytic spectra 
against 148 avian pathogenic E. coli (APEC) strains. The best lytic performance was 
obtained with a combination of tree phages. In order to characterize these phages, an 
effective phage sorting scheme based on phage life cycle, lytic efficiency rate, 
morphology and on phage DNA restriction endonuclease digestion profile (RFLP) was 
conducted. 
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2. MATERIALS AND METHODS 
 
2.1 Escherichia coli isolation  
 
E. coli strains were isolated from organs (liver, spleen, lungs) of infected commercial 
birds, with typical lesions of colibacillosis. Organs were emulsified in sterile saline 
solution 0.85% NaCl (Sigma, Osterode am Harz, Germany) and 0.1 ml of supernatant 
was plated in MacConkey agar (Biokar Diagnostics, Pantin Cedex, France), a selective 
medium for Gram-negative bacilli, which differentiates lactose fermenters (pink-red 
colonies) from non-fermenters bacteria. As approximately 95% of E. coli ferment 
lactose 31, pink red colonies were collected from plates and the specie confirmation of 
the isolates was conducted by using API strips according to manufacturer’s instructions 
(Bio-Merieux, Marcy l'Etoile, France). E. coli isolates were stored in Nutrient Broth 
(Oxoid, Hampshire, United Kingdom) with 20% glycerol at -80ºC.  
 
2.2 E. coli serotyping for the O-antigen  
 
The O-antigen serotyping of E. coli strains was performed using a “kit for serotyping 
avian septicemic E. coli strains”, supplied by the “Laboratorio de Referencia de E. coli 
(LREC)” of the Veterinary Faculty of Lugo, Spain. The kit included 26 antisera: O1, 
O2, O5, O6, O8, O9, O11, O12, O14, O15, O17, O18, O20, O35, O36, O45, O53, O78, 
O81, O83, O88, O102, O103, O115, O116 and O132. If the strain was negative for all 
these antisera, it was considered not typeable (N/T) with this kit. Samples were prepared 
and procedures were carried out according to the supplied protocol.  
 
2.3 Antibiotic susceptibility testing of APEC  
 
The isolated APEC strains were subjected to antibiotic susceptibility testing. The active 
ingredients with systemic action (relayed throughout the blood circulation) in poultry, 
generally used for colibacillosis treatment were selected to perform this antimicrobial 
test. In order to label strains as susceptible, intermediate or resistant, antibiotic 
discriminating concentrations were used: Ampicillin (AMP), 10 µg/disc, Doxycycline 
(DO), 30 µg/disc, Enrofloxacin (ENR), 5 µg/disc, Sulphamethoxazole/ Trimethropim 
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(STX), 25 µg/disc, Nalidixic acid (NA), 30 µg/disc, Pipemidic acid (PIP), 20 µg/disc, 
Tetracycline (TE), 10 µg/disc, Oxolinic acid (OA), 2µg/disc and Amoxycillin (AML), 
30 µg/disc (Oxoid).  
Each strain was plated in Mueller Hinton agar (Biokar Diagnostics), and the discs with 
the antibiotics were placed over the bacteria layer 7. Plates were incubated at 37ºC 
overnight. After this period, the diameter of the clear zone was measured and strains 
classified according to the sensitivity to each antibiotic.  An E. coli reference control 
culture (ATCC 25922) was used for quality control of the test. 
 
2.4 Bacteriophage isolation and purification  
 
Bacteriophages were isolated from samples of poultry sewage, collected randomly from 
Portuguese poultry houses. Under sterile conditions samples were emulsified in Luria 
Bertani (LB) broth (Sigma), and the decanted supernatant obtained from each emulsion 
was added to an early-log grown mixture of eight E. coli strains selected randomly, 
from different O-antigene serotypes. Suspensions were incubated overnight at 37ºC, 
with shaking (120 rpm) and were then centrifuged at 9 000 × g for 10 min (rotor 19776, 
Sigma 3-16k). The supernatant was then filtered through a 0.22 µm membrane, 33 mm 
Millex Filter Units, Durapore® (PVDF) (Millipore, Bedford, MA, USA). The spot test 
method was used as an initial test for the presence of phage. A procedure based on the 
double layer plaque technique was performed 12. Layers of 3 ml of LB 0.6% agar 
(Sigma), previously inoculated with 100 µl of each E. coli strain used above, 6-8 h 
culture were spotted with 10 μl of the filtered suspension. This procedure was 
performed over LB 1.5% agar. Plates were incubated at 37ºC overnight. A clear zone in 
the plate, resulting from the lysis of host bacterial cells, indicated the presence of phage. 
In order to isolate phages from this clear lysis zone, serial dilutions in phage buffer (100 
mmol l-1 NaCl (Sigma), 8 mmol l-1 MgSO4 (Sigma), 50 mmol l-1 Tris (Sigma), pH 7.5) 
were done from the phage stocks obtained above. A colony of the respective hosts 
strains were grown 3-4 h (early-log phase culture) in 5 ml of LB broth. A volume of 100 
µl of phage-containing sample and 100 µl of host culture were mixed with 3 ml of 0.6% 
LB agar, overlaid onto 1.5% LB agar plates and incubated overnight at 37ºC. Phages 
were purified by successive single plaque isolation, from the higher dilutions plates 
where plaques were still distinct. A single plaque was picked from the bacteria lawn, 
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inoculated into an early-log phase host culture, and the lysate plated as described above. 
After repeating the cycle three more times, lysates from single plaques were treated with 
chloroform 4:1 (v/v), mixed and centrifuged at 5 000 × g for 5 min. The phages were 
recovered from the upper phase suspension and filtered trough 0.22 µm. Phages stocks 
were stored at 4ºC.  
 
2.5 Phage lytic spectra of the typed E. coli strains 
 
Bacterial susceptibility to bacteriophage was assayed for the 148 isolated E. coli strains 
by adapting a modified procedure of the traditional double-layer technique 12. Once the 
top agar was solidified at room temperature, 10 μl of the phage lysate suspension of 
about 107 PFU ml-1 was spotted, incubated at 37ºC overnight and examined for the 
presence of a clear zone of lysis. 
 
2.6 Phage amplification  
 
The amplification of each isolated bacteriophage was performed by inoculating 5 ml of 
the purified phage suspensions in 10 ml of a 3-4 h culture (in LB broth) of the 
respective E. coli hosts. It was incubated overnight at 37ºC, with shaking (120 rpm). 
The suspension was centrifuged at 9 000 × g for 10 min and filtered through a 0.22 µm 
membrane.  This procedure was repeated again, by inoculating the resulting phage 
lysate volume in 100 ml of 3-4 h culture followed by incubation overnight at 120 rpm 
and 37ºC. The resultant phage suspension was filtered through a 0.22 µm membrane 
and stored at 4ºC.  
The number of phages present in this suspension was determined according to the 
Adams' method 3 with minor modifications. Successive dilutions of the phage 
suspension were performed in a saline solution (0.85% NaCl) and 100 μl of each 
dilution together with 100 μl of the respective bacterial host suspension were mixed 
with 3 ml of LB 0.6% top agar layer and placed over a 1.5% LB agar bottom layer. 
Plates were incubated overnight at 37ºC.  Phage titration was performed in triplicate. 
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2.7 Bacteriophages life cycle investigation by the induction of infected host 
strains with mitomycin C   
 
In order to evaluate if phages selected based on the lysis efficiency were able to insert 
their genome into bacterial DNA remaining as a prophage, some tests were performed. 
Lambda (λ) phage (DSM 4499), a Siphoviridae temperate phage, and the respective E. 
coli host (DSM 4230) were used as positive controls. Reconstitution, propagation and 
storage of this phage and E. coli host strain were conducted according to the supplier 
instructions (DSMZ, Braunschweig, Germany). 
Each of the host strains were early-log grown in LB broth and 20 µl of the respective 
phage were spotted on the lawns, as described above. After an overnight incubation at 
37ºC, bacteria colonies change in the central lytic zone (resistant colonies) were picked 
(at least 5 colonies) and purified by successive sub-culturing in MacConkey agar, to 
remove attached phage particles. Phage resistance of those isolated strains was 
confirmed by the cross-streaking test and the spot lysis assay, and those phage resistant 
colonies were stress induced with mitomycin C (Sigma). The strains were grown in 200 
ml of LB until an optical density at 600 nm of 0.2 was reached. The induction of phage 
release was attempted via overnight incubation at 37°C, in the presence of mitomycin C 
(1 µg ml-1). A negative control, without mitomycin C was prepared. Bacteria lysate was 
centrifuged at 9 000 × g. The supernatant was filtered through 0.22 µm and tested 
against each phage-sensitive host strain (wild-type (WT)) 22, 28. After an overnight 
incubation at 37°C, bacterial lawns were checked for clear zones. 
 
2.8 Electron microscopy 
 
Phage particles were sedimented at 25 000 × g for 60 min using a Beckman (Palo Alto, 
CA) J2-21 centrifuge with a JA 18.1 fixed-angle rotor. Phages were washed twice in 0.1 
M ammonium acetate, pH 7.0 (Sigma), deposited on copper grids (Ernest F. Fullam, 
Clifton Park, NY) provided with carbon-coated Formvar films (Canemco & Marivac, 
Quebec, Canada), stained with 2% potassium phosphotungstate, pH 7.2 (Sigma) and 
examined in a Philips (Eindhoven, The Netherlands) EM 300 transmission electron 
microscope (TEM), operating 60 kV. Magnification was monitored with catalase 
cristals (performed by Dr. H. W. Ackermann, Laval University, Quebec, Canada). 
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2.9 Bacteriophage purification by CsCl precipitation 
 
An ultracentrifugation method was performed based on a Cesium Chloride density 
gradient. Four different solutions were prepared in phage buffer: 1.70 g ml-1; 1.50 g ml-1 
and 1.30 g ml-1 CsCl (Sigma). After the volume of each phage suspension was 
measured, 0.5 g ml-1 of CsCl was added. These suspensions were ultracentrifuged (XL-
90, Beckman) at 60 000 × g for 2 h at 4ºC. A bluish band indicative of phage particles 
was collected and placed in a microtube 35. A Centricon 20 spin filter unit (Millipore) 
was used to reduce the volume of the recovered CsCl purified phage concentrate. The 
centrifugation was performed at 4 000 × g for 10 min at 4 ºC. The phage concentrate 
was then washed with the phage buffer 1:4 (v/v) and centrifuged with the same settings 
in the filtration module, three more times, to remove all the CsCl. The resulted 
suspension was stored at 4ºC. 
 
2.10 RFLP pattern analysis  
 
Differences between phages were confirmed by comparison between the individual 
restriction fragment length polymorphism (RFLP) patterns. A volume of 200 µl of the 
concentrated phage suspension by CsCl precipitation, was pre-incubated 30 min at 37ºC 
with 1 µl of RNase 20 mg ml-1 (Sigma) and submitted to DNA purification according to 
the protocol provided with a commercial kit, High Pure PCR Template Preparation Kit 
(Roche, Mannheim, Germany). Uncut phage DNA was run at 90 V for 45 min, in a 
0.8% agarose gel (Qbiogene, Irvine, CA, USA) stained with ethidium bromide (Bio-
Rad, Hercules, CA), to verify extraction yield and absence of bacterial genomic DNA. 
XapI, BseGI and SchI restriction enzymes (Fermentas, St. Leon-Rot, Germany) were 
used in order to obtain phage DNA RFLP patterns. A concentration of 5 U µl-1 of each 
enzyme and the respective enzyme buffers 1 × diluted in RNase and DNase free water 
(Biological Industries, M.P. Ashrat, Israel) were added to 6 µl of phage DNA, with a 
final volume of the reaction mixture of 30 µl. Tubes were incubated at 37ºC for 3 h, 
according to supplier instructions. The loading buffer used to improve resolution was 1 
× DNA Loading Dye & SDS Solution (Fermentas) and was added to the samples at 1:6 
(v/v). Tubes were incubated at 65ºC for 10 min and chilled on ice. Samples were loaded 
in a 1 cm thick, 2.0% agarose gel stained with ethidium bromide. Electrophoresis was 
carried out at 45 V for 5 h in a dark place. 
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3. RESULTS 
 
3.1 APEC O-serogroup and antibiotics susceptibility  
 
The most common O-serotype of the 148 isolated APEC strains was the O78 with a 
frequency of 40.5%, followed by O2, O5 and O88 representing each from 5.2% to 6.9% 
of the isolated bacteria. It was not possible with the kit used to type 34.7% of the 
bacterial strains. E. coli serotypes as O1, O8, O11, O15, O20, O53, O86 and O103 were 
present at a low frequency (from 0.6 to 1.7%), while O6, O9, O12, O14, O17, O18, 
O35, O36, O45, O81, O83, O102, O115, O116 and O132 were not detected (Figure II.1 
.  
 
 
Figure II.1 Relative frequency (%) of the APEC O-serotypes.  
 
E. coli strains were also grouped according to the respective O-serotype, by strain of 
birds, age or species, according to the source of isolation.  
Figure II.2 refers to the relative distribution of O-serotypes per group of birds. It is 
possible to verify that different O-serotypes infected the same group of birds. For 
example, serotypes like  O1, O2, O78 and N/T were isolated from laying hens, O8, O15, 
O78, O86, O88, O103 and N/T were isolated from broilers,  O1, O2, O5, O11, O53, 
O78, O88, O103 and N/T from label chickens, O2, O5, O20, O78, O88 and N/T were 
found in chicks, O78 and N/T in breeders and O2, O5, O78 and N/T were isolated from 
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turkeys. It was observed that the isolated O-typeable strain more frequent in all the 
groups was the O78.  
 
 
 
 
 
 
 
 
Figure II.2 Relative frequency (%) of E. coli main isolated serotypes, according to the 
birds’ strain, specie or age. O-serotypes described as “others” are O8, O11, O15, O20, 
053, 086 and O103, and were found in bacteria collected from broilers, 2.9% O8, 2.9% 
O15, 2.9% O86 and 2.9% O103, label chickens, 1.4% O11, 1.4% O53 and 2.8% O103 
and chicks (5.6% O20) (  O1; O2; O5; O78;   O88;    NT;    others). 
 
The isolated strains were then subjected to an antibiotic sensitivity test and the 
percentages of susceptible, intermediate or resistant strains to each antibiotic are present 
in Figure II.3.  
It was observed that 80 to 90% of the strains were resistant to TE, DO, OA and NA, 70 
to 75% were resistant to AMP and PIP, 66.5% to AML, 61.6% to STX and 47.5% to 
ENR. The active ingredient with higher effectiveness to this group of strains was ENR, 
active against 50.8% of the APEC. 
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Table II.1 Bacteriophages lytic score (%) by E. coli O-serotype.  
  phi F78E phi F258 E phi F2589E phi F61E phi F5318E 
O
-s
er
og
ro
up
 
O1 0.00 0.00 0.00 0.00 0.00 
O2 63.64 9.09 0.00 18.18 9.09 
O5 35.29 5.88 5.88 47.06 5.88 
O15 100.00 0.00 0.00 0.00 0.00 
O20 0.00 0.00 0.00 0.00 0.00 
O53 0.00 0.00 0.00 0.00 0.00 
O78 8.33 30.73 14.06 23.96 22.92 
O88 26.32 0.00 26.32 47.37 0.00 
O103 100.00 0.00 0.00 0.00 0.00 
N/T 48.39 16.13 6.45 19.35 9.68 
                             
Table II.2 Bacteriophages sensitive strains (%).   
Phage  phi F78E phi F258 E phi F2589E phi F61E phi F5318E 
Sensitive strains (%) 35.14 44.59 23.65 47.97 33.11 
   
Figure II.4 illustrates the best phage association according to the higher percentage of 
lysed strains, in groups of two, three, four and five phages. When combining them in 
groups of two, the strongest lysis association was between phi F78E and phi F61E 
(60.4%). Groups of three phages, phi F78E, phi F258E and phi F61E, presented a higher 
lysis percentage, 70.5%. Associations of four and five phages are able to lyse, 
respectively 71.8% and 72.5% and thus does not bring a relevant advantage for lytic 
spectra range when compared with an association of three phages. Based on these 
results, the phages selected for further characterization were phi F78E, phi F258E and 
phi F61E. 
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Figure II.4 Best phage associations according to the higher percentage of lysis of the 
tested Escherichia coli strains: A- phi F61E (45.0%); B- phi F78E + phi F61E (60.4%); 
C- phi F78E + phi F258E + phi F61E (70.5%); D- phi F78E + phi F258E + phi F61E + 
phi F5318E (71.8%); E- phi F78E + phi F258E + phi F2589E + phi F61E + phi F5318E 
(72.5%). 
 
3.3 Characterization of phages phi F78E, phi F258E and phi F61E  
 
Phages phi F258E and phi F61E formed very clear lytic zones on their hosts (H816E 
and H161E, respectively) exhibiting no resistant bacteria. Conversely, phi F78E induced 
the formation of resistant colonies on H561E lawns after subculture, which may be an 
indication of lysogeny. Temperate phages integrate into the DNA hosts and only lyse 
the cells under certain conditions. Stress induced infected cells with temperate phages 
usually results in the release of the phage. So, the mitomycin C assay with the phi F78E 
resistant bacterial cells was performed. Infected E. coli DSM 4230 with λ bacteriophage 
was used as a positive control. In the assay no clear zone was found after stress inducing 
phi F78E resistant bacteria, which indicated that phi F78E is not temperate.   
Electron micrographs demonstrated that all phages do not possess any lipidic envelope. 
Phages phi F78E and phi F61E had a neck with a tiny collar and a contractile tail. Phi 
F78E has caudal fibers (20 × 2 nm) (Figure II.5A). Phi F78E and phi F61E capsids were 
103 × 42 nm and the tails 100 × 17 nm (Figures II.5A and II.5C, respectively). Phi 
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Bacteriophages have several characteristics that make them potentially attractive 
therapeutic agents against bacterial infections. One of them is the high specificity and 
effectiveness in lysing targeted pathogenic bacteria.  Due to phages high specificity, 
they are likely to have a relatively narrow host range, and so, the disease agent has to be 
isolated and a bacteriophage lysis test must be customized to the specific pathogenic 
bacteria 25. 
From another perspective, the treatment of a disease with bacteriophage might benefit, 
if instead of one, a cocktail of phages effective against the most part of the bacteria that 
are known to cause the disease is used.  From this point of view, it would be useful to 
develop a bacteriophage therapeutic product based on the best phage associations, 
increasing the antimicrobial range of the product 13, 20, 25, 39, 42, 43. This was the 
underlying reason for testing the efficacy of several isolated E. coli phages against a 
pool of the isolated APEC strains resistant to the most common antibiotics. From the 
five phages isolated, two revealed broad lytic spectra, being phi F61E the most effective 
phage, lysing 48.0% of the bacterial strains. The association of phi F78E, phi F258E 
and phi F61E was effective for 70.5% of the strains. It is important to stress that with 
only three phages, a large range of APEC strains were covered, which is better than the 
most effective antibiotic, the ENR with 50.8% of efficacy (Figure II.3). A significant 
increment in the lysis efficiency combinations of four or five phages was not found 
compared to the efficacy observed with three phages (71.8% and 72.5% of lysed strains, 
respectively). In fact, an association of more than three phages would be even 
disadvantageous, because the economic recourses necessary to characterize and produce 
different phages would be higher. Based on this assumption, phi F78E, phi F258E and 
phi F61E were selected for further characterization. 
The phages morphological characteristics observed by Transmission Electronic 
Microscopy (TEM) revealed that phi F78E and phi F61E belong to Myoviridae 
taxonomic family and seem to be 16-19 type phages, roughly like T4. The same phage 
types have already been isolated from sewage and characterized morphologically by 
Ackermann et al. 2, and later by Ackermann and Nguyen 1. Similar to phi F78E and phi 
F61E, the two phages described by those authors showed contractile tails of 100×7 nm 
and 94×15 nm and elongated heads with 104×43 or 102×57 nm in diameter. The same 
authors described that in those phage types, heads resembled superficially those of T-
even phages and appeared to be mostly oval. Tails of these phages were complex and 
consisted generally, of a neck, a base plate and tiny caudal fibres, similar to the phages 
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characterized in this work. Those phages were so far described for Salmonella, so, to the 
authors knowledge, this was the first time that 16-19 phages are described as being 
effective against E. coli strains. Phi F258E seemed to be a Siphoviridae, T1-like, 
already described for E. coli 47.  
One of the major concerns in the use of phages for therapy purposes is to guarantee that 
the phages do not integrate into the DNA hosts. The morphological characteristics of 
these phages are similar to those described as lytic; nevertheless a mitomycin C stress 
inducement was performed to confirm that phage phi F78E is not temperate, because 
resistant colonies were recovered from the interior of the phage clear zone.  
The three phages presented different structure and host range, and therefore are distinct. 
This was also corroborated by their different RFLP patterns.  
In short, in this work three phages belonging to the Myoviridae and Siphoviridae 
families, isolated from poultry sewage, showed to be effective against 70.5% of the 148 
isolated APECs, most of which were resistant to the majority of antibiotics tested. 
Morphological and genetic characterization of these phages suggests that they belong to 
different phage-types. Taking together all these results it can be suggested that these 
three phages combined in a therapeutic cocktail would be a more efficacious therapy 
over conventional antibiotic therapy.  
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1. INTRODUCTION 
 
Lytic bacteriophages (phages) are viruses that infect and promote bacteria lysis through 
a multiple-step process: they multiply in the host bacteria and lyse it at the end of the 
cycle, after immediate replication of new phage particles. They are considered to be 
good candidates for antimicrobial therapy, as they provide an opportunity to control 
bacterial infections. Bacteriophages are safe once they exclusively infect bacterial cells, 
having no activity against animal or plant cells. Like all viruses, phages are 
metabolically inert in their extra cellular form and they are ubiquitous in nature 10. 
Nevertheless, as phage infections culminate in lysis of bacteria, there is a consequent 
release of cell wall components to the environment as cell debris. In this process, Gram-
negative bacteria release endotoxin into the environment, whose biological activity is 
associated with complexes of lipopolysaccharides (LPS), present in the outer layer 
membrane. This can lead to undesired side effects on phage therapy. The LPS toxicity is 
associated with the lipidic component of the molecule, known as “lipid A”, while the 
immunogenicity is associated with the polysaccharide component, known as “O-
specific side chain” or “O-antigen” 2, 5, 18, 23, 24). For that reason, LPS are present in the 
cellular debris in crude phage lysates, easily passing through filters used to remove 
whole bacteria from phage suspensions 24.  
The endotoxins may induce a variety of inflammatory responses being often part of the 
pathology of Gram-negative bacterial infections. Although animals vary in their 
susceptibility to endotoxins, the sequence of pathophysiological reactions follows a 
general pattern: a latent period followed by physiological distress. Immunologic and 
neurological system activation, induction of blood coagulation, general metabolic 
effects, alteration of blood cell populations, pyrogenicity, production of endotoxic shock 
and hepatotoxicity are some of the known reactions to an endotoxin parenteral  
challenge, promoting symptoms like fever, diarrhoea, prostration and, in many cases, 
shock and death 5, 25. The study of the way to remove endotoxins from solutions 
intended to be used in humans or animals is therefore an important area of study in 
applied Biotechnology. However the success of this procedure is greatly dependent on 
the initial composition of the mixture 2, 17. Ultrafiltration and size-exclusion 
chromatography should theoretically provide a way of separating components differing 
in molecular mass. However, the application of these two down-stream processes in the 
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purification of phages only allows a partial removal of the contaminants present in the 
phage suspension. In fact, despite their relatively low molecular weight (4-20 kDa for 
LPS monomer), endotoxins are not effectively removed as they tend to aggregate 
forming structures similar to micelles and vesicles, ranging in molecular weight from 
300 000 to 1 million, with diameters up to 0.1 μm 2, 24. There have been reported other 
approaches to achieve the destruction or removal of endotoxins, like hydrolysis with 
acid or base, oxidation, alkylation, heat treatment and treatment with polymicin B 6. 
However, all these approaches must be evaluated considering the economical viability 
of the scale-up of the process and the possibility of compromising the recovery rate of 
the desired product, in this case the phages. According to Petsch and Anspach (2000)17, 
the question of how endotoxin removal can be carried out in an economical way has 
occupied many investigators and has been the reason for process rearrangements in 
many cases.  
In this work, an in vivo trial with an E. coli phage crude lysate, administered 
intramuscularly to chickens, was conducted in order to evaluate the endotoxin effect and 
to assess the level of importance of endotoxin removal in ensuring the safety of this 
phage product for the target species. 
 
2. MATERIALS AND METHODS 
 
2.1 E. coli phage lysate   
 
Crude phage suspensions were prepared by inoculating a single phage plaque of the 
phages phi F78E, phi F258E and phi F61E in 10 ml of the respective E. coli host 
H561E, H816E and H161E, mid-log grown (3-4 h) in Luria Bertani (LB) broth, (Sigma) 
(as described in Chapter II, Section 2.4). This was followed by an overnight incubation 
at 37ºC with shaking (120 rpm). The suspension was then centrifuged (9 000 ×g) for 10 
min (rotor 19776, Sigma 3-16k), filtered through a 0.22 µm membrane (Millipore) and 
following the same procedure as previously described, inoculated again in 100 ml of  
mid-log grown culture of the respective E. coli host. The incubation was performed at 
37ºC with shaking (120 rpm), the centrifugation was at 9 000 ×g for 10 min and the 
filtration was through 0.22 µm. The phage crude lysate was stored at 4ºC. The number 
of phages in this suspension was determined according to the Adams’ method 1 with 
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minor modifications. Briefly, successive dilutions of the phage suspension were 
performed in phage buffer (100 mmol/l  NaCl (Sigma), 8 mmol/l MgSO4 (Sigma), 50 
mmol/l Tris (Sigma), pH 7.5) and 100 μl of each dilution together with 100 μl of the 
respective bacteria host suspension were mixed with 3 ml of LB 0.6% top agar layer 
and placed over a 1.5% LB agar bottom layer. Plates were incubated at 37ºC for 12 h 
and phages enumerated in the higher dilution with distinct plaques.  Phage titration was 
performed in triplicate. 
 
2.2 Measurement of endotoxin concentration  
 
The concentration of LPS present in the E. coli phage lysate was measured using the 
Limulus Amebocyte Lysate assay (LAL) (Bio-Whittaker), which is based on the 
activation of Limulus Lysate by endotoxins 18. The procedure was carried out according 
to the supplier instructions, using a spectrophotometer (Bio-TEK Synergy HT). This 
method was approved by FDA for detection and quantification of endotoxins 7.  
 
2.3 Experimental  Design  
 
This study was conducted according to the Federation of European Laboratory Animal 
Science Associations (FELASA) principles of animal welfare, and the experiment was 
designed in accordance to the European Council Directive of 24 November 1986 
(86/609/EEC) guidelines, on the approximation of laws, regulations and administrative 
provisions of the member States regarding the protection of animals used for 
experimental and other scientific purposes. 
Thirty-six healthy 7-week-old growers (Rhode Island Red) were used. Two groups of 
18 chickens were randomly selected and housed, 3 per cage, in a temperature and 
relative humidity controlled animal room, with a 12 h light/ 12h dark cycle. Birds were 
individually identified by leg rings. Feed and water were provided ad libitum. A volume 
of 1 ml of the previously prepared phage suspension and 1 ml of sterile LB broth were 
injected intramuscularly, respectively in the challenged group (CHG) and in the control 
group (CG), only in the first day. The chickens’ body weight (BW) was recorded the 
day before and every day after challenge. In order to avoid unnecessary discomfort to 
the animals, the evaluation of chickens’ reaction to challenge was done based on 
behavior observation, taking in account specific signs: healthy chickens were 
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recognized by their standing up position, with the neck strong and straight, flat feathers 
against the body and high frequency of seeking food and water. If, on the other hand, 
chickens were sitting, lying still, with the neck weak and shrunken, raised feathers, and 
not looking for food or water, they were reported as prostrated.  Food and water 
consumption were recorded daily. On day 7, all chickens were euthanized by 
isofluorane (IsoFlo®, Abbott) inhalation and submitted to post mortem examination. 
 
2.4 Statistical analysis  
 
Statistical analysis was undertaken for each parameter assessed in the study: BW gain, 
feed and water intake per gram of BW. CHG means were compared with CG means at 
each data collecting period. Statistical variance analysis was performed using Kruskal-
Wallis test in SPSS v15.00 software. Statistical significance was tested at P = 0.05. 
 
3. RESULTS 
 
3.1 E. coli phage lysate  
 
The E. coli phage lysate is a mixture of three phages phi F78E, phi F258E and phi 
F61E, with the concentration of each phage being 1.67×108 PFU/ml, 2.5×108 PFU/ml 
and 3.0×108 PFU/ml, respectively. The LAL test revealed that the LPS concentration 
present in this suspension was 8.21×104 Endotoxin Units (EU)/ml. 
 
3.2 In vivo challenge with phage lysate  
 
A volume of 1 ml of phage lysate was administered intramuscularly to the chickens of 
the CHG, with the total amount of LPS being, in average, 2.32×105 EU/kg BW.  
During the in vivo experiment, bird prostration was only observed during the day of the 
inoculation (day 1) in CHG. One bird died one hour after inoculation but in the post 
mortem analysis no macroscopic lesions were detected in internal organs. During the 
following six days, no visual differences were found in the chicken’s activity between 
the two groups. Respecting to the BW gain (Figure III.1), it was observed that at day 1 
and day 6, this parameter decreased significantly in CHG (P = 0.043 and P = 0.010, 
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respectively). The feed and water intake per gram of BW did not diverge significantly 
between groups (Figure III.2 and III.3). Apparently, there was a decrease in the water 
intake per gram of BW at day 1 in CHG, but with no relevant differences between 
groups (P = 0.065). At day 4, there was a significant decrease (P = 0.035) in CHG, 
however this tendency was no longer observed in the following days. 
 
 
Figure III.1 Chickens’ daily BW gain. In the figures, the solid line   represents 
CG variation in body weight gain and the dashed line  represents the CHG 
variation. Error bars represent standard deviations of experimental data from the six 
cages of three animals each. *Statistically different from CG. 
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Figure III.2 Chickens’ feed consumption per gram of BW. In the figures, the solid line  
 represents CG variation in body weight gain and the dashed line  
represents the CHG variation. Error bars represent standard deviations of experimental 
data from the six cages of three animals each.  
 
Figure III.3 Chickens’ water consumption per gram of BW. In the figures, the solid 
line   represents CG variation in body weight gain and the dashed line  
represents the CHG variation. Error bars represent standard deviations of experimental 
data from the six cages of three animals each. *Statistically different from CG.  
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4. DISCUSSION 
 
Phage therapy has been considered an important alternative to the administration of 
antibiotics in the treatment of severe E. coli infections in birds 9, 10. One of the main 
concerns of this approach is the presence of endotoxins in the phage crude lysate 19. In 
the present work, 8.21×104 EU/ml LPS were found in the prepared phage cocktail used. 
Nevertheless, the chickens were challenged with 1ml of this phage lysate containing 
approximately 2.32×105 EU/kg BW, which was not supposed to be lethal, since, and 
according to Culbertson and Osburn (1980) 5, the lethal dose of Escherichia coli 
endotoxins to chickens is ≥ 50 mg/kg or ≥ 5×108 EU/kg (1 EU/ml ≈ 10 ng/ml). 
Kokosharov (2002) reported that little is known about LPS activity in chickens and 
sometimes experimental data are conflicting and divergent. It should be referred that the 
phage lysate administered to the chickens has 10 times the volume, and therefore might 
have about 10 times the LPS content of the phage cocktails used for therapeutic 
purposes as described by Huff and their colleagues (2004, 2005) 9, 10. These authors did 
not observe any harmful effects on chickens’ health and advise a phage concentration in 
therapeutic mixtures ranging between 107 and 109 PFU/ml 9, 10. During the in vivo trial, 
the birds challenged with the phage lysate, as compared to the CG, exhibited prostration 
and decreased feed and water intake only during the day of inoculation. During the 
following days, chickens’ behavior did not show visual differences between groups. 
Similar findings were reported by Smith et al. (1978) 22 during an experiment with 
endotoxins from Salmonella enterica serovar Gallinarum administered to 14-day-old 
chicks. Despite the observation of some clinical illness without mortality a few hours 
after intravenous injection of 1.5×107 ng/kg LPS, most of the responses returned to 
normal within 24 to 48 h. Also Kokosharov (2002) 12 observed illness in cockerels one 
hour after injection of 5.0×107 ng/kg LPS. Birds were described as standing in the 
corners of the cages with signs of depression, reluctance to move, somnolence, loss of 
thirst and appetite, and diarrhea, which all gradually disappeared. This author did not 
report any death among the cockerels challenged.  
In the present work, one chicken died one hour after the intramuscular inoculation, 
probably due to an anaphylactic shock, as no visible lesions were found at necropsy. 
The statistically significant decrease of BW gain in CHG at day 1 was probably due to 
the chickens’ prostration and apparent loss of appetite. At day 6, the differences 
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between groups might be explained by the occurrence of an unexpected factor during 
the experiment: some feeders of the CG were found empty in the morning, for the first 
time since the beginning of the housing. As feed had to be provided ad libitum, feeders 
were immediately refilled. This happened a few hours before birds weighing and thus 
might had contributed to the higher average weight in the CG. Concerning the water 
intake per gram of BW, results illustrate an apparent decrease at day 1 in CHG without 
statistic relevance, probably also due to chickens’ prostration. A reasonable explanation 
for the significant decrease of this parameter at day 4 was not found. However, as in the 
following days CHG and CG presented the same water intake, this occurrence was not 
taken into significant account. 
The absence of macroscopic lesions in the internal organs of the euthanized birds 
suggested that the phage lysate did not cause any visible internal injurious effect. 
Many studies have already been carried out to evaluate endotoxin action in humans and 
other animals for several pharmaceutical purposes, like toxicity evaluation of antibiotic-
induced endotoxin released in organism, water purification for dialysis, etc. 3, 8, 13-16, 20, 
21. The variation in sensitivity to endotoxin among species and the higher resistance of 
chickens to endotoxin effects as compared to mammals 4, 5, 11, 22, does not encourage the 
use of results from trials obtained with other animals to support the results obtained in 
this trial.  
Summarizing, despite an initial prostration, no adverse effects were found in the 
chickens challenged by the phage crude lysate containing 8.21×104 EU/ml endotoxins, 
and thus, it was possible to conclude that phage crude lysate is not toxic for chickens. 
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  Escherichia coli (E. coli) can cause severe respiratory and systemic 
infections in chickens, and is often associated with significant 
economic losses in the poultry industry. Bacteriophages (phages) 
have been shown to be potential alternatives to the antibiotics in the 
treatment of bacterial infections. To accomplish that, phage particles 
must be able to reach and remain active in the infected organs. The 
present work aims at evaluating the effect of the route of 
administration and the dosage in the dissemination of three 
coliphages in the chicken’s organs. In vivo trials were conducted by 
infecting chickens orally, by spray and intramuscularly with 106, 107 
and 108 PFU/ml suspensions of three lytic phages: phi F78E 
(Myoviridae), phi F258E (Syphoviridae), and phi F61E 
(Myoviridae). Birds were euthanized 3, 10 and 24 h after challenge 
and the phage titre was measured in lungs and air sacs membranes, 
liver, duodenum and spleen. When administered by spray, the three 
phages reached the respiratory tract within 3 hours. Oral 
administration also allowed all phages to be recovered in lungs, but 
only phi F78E was recovered from the duodenum, the liver and the 
spleen. These differences can be explained by the possible 
replication of phi F78E in commensal E. coli strains present in the 
chickens gut, thus leading to a higher concentration of this phage in 
the intestines that resulted in systemic circulation of phage with 
consequent phage in organs. When phages were administrated 
intramuscularly, they were found in all the collected organs. Despite 
this better response, intramuscular administration is a non 
practicable way of protecting a large number of animals in a poultry 
unit. In general, the results suggest that oral administration and 
spray allowed phages to reach and to remain active in the 
respiratory tract and can, therefore, be considered promising 
administration routes to treat respiratory E. coli infections in the 
poultry industry.  
Keywords: bacteriophage; E. coli respiratory infection; 
dissemination; chicken.
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1. INTRODUCTION 
 
The colibacillosis, caused by Escherichia coli, is a severe infection of farmed poultry 
leading to high morbidity and mortality 2. The increasing incidence of antibiotic 
resistances in E. coli and the restriction of the use of antibiotics in animal production 20 
emphasize the importance of the evaluation of alternative antimicrobial therapies. 
Once bacteriophages (phages) are obligatory and exclusive bacterial parasites, they can 
act as antimicrobial agents, a fact that has encouraged researchers to test their potential 
as therapeutic agents. Phages are ubiquitous in nature and are known to inhabit animals 
and humans. Phages penetrate the blood stream and other tissues very freely upon their 
administration by different routes. The potential of phages as antibacterial agents lies on 
their ability to destroy bacterial cells at the end of an infectious cycle. The simultaneous 
releasing of the progeny leads to a concentration of phages in the places where bacterial 
infection occurs, retaining their full biological activity 10. Moreover, phage therapy only 
needs to decrease the number of infecting bacteria to a level that allows the host 
defences to overcome the remaining infection 21. 
However, phage therapy may fail if phages are unable to reach the target organs in the 
concentrations needed to trigger the infection cycle. Phages might be intolerant to the 
gastrointestinal (GI) tract conditions or inactivated by the immune system. Therefore, it 
is of utmost importance to understand the dynamics of phage dissemination in the target 
organism in order to predict the success of phage therapy. In this study, the 
dissemination of three different coliphages was assessed, taking into account the phage 
type, the administration route and the dosage.  
 
2. MATERIALS AND METHODS 
 
2.1 Bacteriophages Amplification  
 
The phages used in this study were isolated from poultry sewage and screened against a 
pool of 148 avian pathogenic E. coli (APEC) strains. Phi F78E, phi F258E and phi 
F61E, were respectively lytic for 34.9%, 23.5% and 45.0% of APEC strains and the 
three phages associated were active against 70.5% of the strains. The morphological 
characterization of the phages revealed that phi F78E and phi F61E are 16-19 type 
phages, have capsids of 103 × 42 nm and contractile tails of 100 × 17 nm and both 
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belong to Myoviridae. Although morphologically similar, they were shown to be 
genetically different. The other phage, phi F258E, is a Siphoviridae, T1-like phage with 
a circular head of 62 nm diameter and a flexible tail of 160×8 nm (Chapter II). Phages 
replication was performed by inoculating 10 ml of each phage in 100 ml of the E. coli 
hosts H561E, H816E and H161E respectively for phages phi F78E, phi F61E and phi 
F258E and mid-log grown in Luria Bertani (LB) broth. This was followed by an 
overnight incubation at 37ºC with shaking (120 rpm). This suspension was then 
centrifuged at 9 000 × g for 10 min (rotor 19776, Sigma 3-16k), filtered through a 0.22 
µm membrane and stored at 4 ºC.  
The bacteriophage concentration was determined according to the plaque assay method 
described by Adams 1. A volume of 100 μl of successive dilutions of the phage 
suspension was mixed with 100 μl of the respective bacteria host suspension (3-4 h 
culture) and 3 ml of LB 0.6 % melted agar. This suspension was poured onto a 1.5% LB 
agar plate and incubated at 37ºC, overnight.  The suspensions volume was adjusted in 
order to obtain the desired phages concentration.  
 
2.2 Bacteriophages viability under in vitro simulated chicken 
gastrointestinal tract conditions 
 
The simulated conditions of the chicken Gastrointestinal (GI) tract were based on pH, 
enzyme activity and feed residence time on each gut compartment.  
The phage buffer (NaCl, MgSO4, Tris 1M, pH 7.5) was used as the control solution. 
This buffer was adjusted to different pH values by adding 1M of HCl, according to the 
pH defined for the respective segments of the chicken GI tract (adapted from Chang and  
Chen (2000)7 and Gauthier (2002) 11): crop and proventriculus (pH 4.5); gizzard (pH 
2.5-3.5), small intestine (pH 5.8) and large intestine (pH 5.7). Each phage suspension, 
1.0×108 PFU/ml, was added to the prepared buffers at 1:10 and incubated with slow 
shacking, at 42 ºC, anaerobically, for the following periods: 15 and 30 min for pH 4.5, 
(simulating respectively the crop and the proventriculus residence times), 90 min for pH 
2.5 and 3.5, 90 min for pH 5.8, and 15 min for pH 5.7. The control solution was 
incubated for 90 min.  
The susceptibility to the GI tract enzymes was performed by incubating the phage 
suspensions with enzymes, in the conditions previously described. For that, 3 210 U/ml 
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of pepsin (Sigma) 15 were used to simulate the proventriculus (pH 4.5) and the gizzard 
(pH 2.5) and 535 U/ml of trypsin (Sigma) to simulate the small intestine (pH 5.8). 
Following incubation, the phage concentrations were measured and compared by the 
plaque forming unit method, as described above.  
 
2.3 Experimental design 
 
Experiments were designed and conducted in accordance with the Federation of 
European Laboratory Animal Science Associations (FELASA) principles and the 
specific guidelines of animal welfare 31, based on the European Council Directive of 24 
November 1986 (86/609/EEC) guidelines regarding the protection of animals used for 
scientific experimental purposes. According to those principles, the lowest number of 
animals necessary to reach the proposed goal in an in vivo experiment must be used. A 
total of 94 healthy 7-weeks-old growers (Rhode Island Red), obtained in a local poultry 
house, were housed in batteries and subjected to a 5-days acclimation period. The 
chickens were monitored for the presence of commensal enterobacteria sensitive to phi 
F258E, phi F61E and phi F78E. For that purpose, cloacae swabs were collected in 
triplicate, plated in MacConkey agar (selective and differential medium for gram-
negative bacteria) and incubated at 37ºC. Five to eight pink colonies (micro-organisms 
that ferment lactose, as E. coli) were selected and picked from each plate, incubated 
separately in 10 µl of LB broth at 37ºC for 3 to 4 h, and spread in a lawn. Then, they 
were tested for phage sensitivity: 20 µl of phage were dropped on these bacteria lawns, 
and incubated at 37ºC overnight. Plates were then checked for clear zones.  
Parallel trials were conducted to determine the efficacy of phage administration to 
chicken organism, concerning the route (oral, spray and intramuscular) and the dosage 
(1.0×106 PFU/ml, 1.0×107 PFU/ml and 1.0×108 PFU/ml). Feed and water was available 
ad libitum. Groups of 3 animals were challenged with 1 ml of the phage suspension at 
each of the indicated phage concentration, orally with a syringe, by spray directly to the 
beak or intramuscularly by injection in the chest muscle. One group, not challenged 
with the phages, was used as a control group. Birds were euthanized by isofloran 
e inhalation (IsoFlo®, Abbott) 8, 3, 10 and 24 h after challenge. At necropsy, carcasses 
were dissected and different organs and tissues (lungs and air sacs membranes, liver, 
duodenum and spleen) were carefully excised, weighted and emulsified individually in 
LB broth at 1:10 (w/v). The supernatants were decanted, centrifuged at 9 000 × g for 10 
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min and filtered through 0.22 µm. The phage concentration was measured in each 
sample, as described above. 
 
3. RESULTS 
 
3.1 Bacteriophages susceptibility to in vitro GI tract conditions  
 
Figure IV.1 presents the percentage of logarithmic reduction of each phage 
concentration when submitted to acidic and enzymatic conditions similar to those found 
in some segments of chicken GI tract, comparatively to the concentration at pH 7.5. 
Among the three coliphages, phi F78E was the most affected to low pH values. In fact, 
the concentration of the other two phages only slightly declined when these phages were 
subjected to simulated gizzard conditions. The logarithmic concentration of phages phi 
F258E and phi F61E was reduced by 27.92 % and 26.38 % at pH 2.5 and by 1.94 % and 
1.86 % at pH 3.5, respectively. Phi F78E lost all its activity (detection limit ≥ 1.0×101 
PFU/ml) at pH 2.5 and a logarithmic reduction of 4.48 % at pH 3.5. The pepsin added to 
the solution with pH 2.5 did not demonstrate any additional effect on the reduction of 
phages concentration (Figure IV.1B). Phi F78E was not significantly susceptible to the 
other simulated GI tract conditions, along with phages phi F258E and phi F61E (Figure 
IV.1A). The activity of pepsin at pH 4.5 and trypsin at pH 5.8 induced a phage log 
concentration reduction of 1.57 % and 2.65 % respectively (Figure IV.1B). 
 
 
 
 
 
 
 
The bacteriophage therapy for colibacillosis in poultry 
 
 73  
A.  
B.  
Figure IV.1 Logarithmic reduction (%) of phage concentration, after submission to 
simulated chicken GI tract pH conditions (A.) and pH + enzymatic conditions (B.), 
comparatively to pH 7.5 (  phi F78E;  phi F258E;  phi F61E) 
 
3.2 Bacteriophages distribution in chicken organisms 
 
Preliminary studies to detect host-susceptible strains to the three studied coliphages 
revealed the presence of a commensal E. coli strain susceptible to phi F78E. 
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The results of phages detection in the animal organs after oral and spray administration 
are presented in Tables IV.1 and IV.2, respectively. When administered by spray, all the 
three phages reached the respiratory organs.  The oral administration also allowed phi 
F61E and phi F258E to reach the lungs and the air sacs membranes, being recovered 
from these organs at least at 10 h from challenge. The phage phi F78E remained in the 
same organs for the whole tested period when administered at 108 PFU/ml. Phi F78E 
was recovered from the duodenum at least 3 h after the oral administration of 107 and 
108 PFU/ml suspensions; however, it was not possible to recover the other two phages 
(phi F61E and phi F258E) in this organ. Nevertheless, when spray administration was 
employed, all phages were found in the duodenum, and phi F78E titres were higher than 
the other phages (data not shown). Phi F78E could be isolated from the liver and spleen 
after oral and spray administration.  
 
Table IV.1 Presence (+) or absence (−) of phages in organs and tissues after oral 
administration, according to the initial phage concentration and the time of slaughter (3, 
10 and 24 h). A: lungs and air sacs; B: liver; C: duodenum; D: spleen.  
 
 
Table IV.2 Presence (+) or absence (-) of phages in organs and tissues after spray 
administration, according to the initial phage concentration and the time of slaughter (3, 
10 and 24 h). A: lungs and air sacs; B: liver; C: duodenum; D: spleen. 
 
 
The presence of phages in organs following intramuscular injection is shown in Table 
IV.3. All the phages were recovered from the chicken lungs and air sacs membranes, the 
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liver and the spleen, at least 3 h after challenge (except for phi F61E, not found in the 
liver when administered at 106 PFU/ml). Phages remained in the spleen for all the 
experimental period. When injected at 108 PFU/ml, all the phages reached the intestine. 
  
Table IV.3 Presence (+) or absence (-) of phages in organs and tissues after 
intramuscular administration, according to the initial phage concentration and the time 
of slaughter (3, 10 and 24 h). A: lungs and air sacs; B: liver; C: duodenum; D: spleen. 
 
 
Figure IV.2 presents the concentrations of phi F78E, phi F258E and phi F61E recovered 
in the lungs and air sacs, the liver and the spleen, after intramuscular injection of 
1.0×108 PFU. Data refers to phages enumeration at 3, 10 and 24 h of challenge. 
In general, all the phages were rescued in the spleen, the liver and the lungs 3 h post 
administration, with the maximum concentration of phi F78E and phi F258E observed 
in the spleen and of phi F61E in the liver.    
Concerning the phage titres measured in the chicken’s lungs, it was observed that, for 
all administered concentrations and for all the phages, the higher phage titres were 
detected 3 h after phage administration. On the contrary, 10 h after challenge, no phage 
was detected in these organs.  
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A.    
B.     
C.       
Figure IV.2 Concentration (PFU/ml) of phi F78E (A.), phi F258E (B.) and phi F61E 
(C.) found in lungs and air sacs, ( ) liver (  ) and spleen ( ) after 3, 10 and 24 h of 
the intramuscular administration of 1.0x108 PFU/ml. The inset in Figure IV.2 A 
illustrates, in an amplified scale, the values of phage concentration in organs at 10 h 
post-administration.  
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4. DISCUSSION 
 
Extra-intestinal pathogenic E. coli, termed avian pathogenic E. coli (APEC) possess 
specific virulence attributes commonly causing respiratory and systemic infections in 
poultry (chickens and turkeys), namely colibacillosis 34, 2. In a phage therapy 
perspective, phages must be able to reach the infected organs, a fact that might be 
dependent on the mode of administration, the administration titre and the phage itself. In 
fact, the overall results presented in this manuscript demonstrate that the phage type, the 
administration route and the dose delivered, were all factors contributing to variability 
of bacteriophage dissemination in tissues.  
Phages have been administered orally, topically, by spray, directly into body tissues or 
systemically 3, 4, 16-20, 24, 26-29. The method chosen for phage administration must 
guarantee the contact between phage particles and target pathogens. It is therefore 
important to ensure that, whatever route of administration, phage delivery to the 
infected organs will take place. In the particular case of avian respiratory infections 
caused by APEC, phages must be able to reach lungs and air sac membranes. On the 
other hand, from the practical point of view, some routes, like systemic ones, would be 
unfeasible, due to the large number of birds in a poultry unit. In this specific case, the 
most practical methods would be the oral inoculation in feed or water, or the aerosol 
(spray) delivery of phages. In fact, other management practices employ one or both of 
this routes for suspension delivery, like most of the vaccines application 6 or some 
antibiotic and probiotic administration 12. Oral administration, however, could be 
considered an obstacle due to the potential phage inactivation during its passage through 
the acidic gut compartments 22.  
Therefore, prior to the in vivo experiments, the survival of the three coliphages in the GI 
tract was assessed in vitro by submitting the phages to simulated gut conditions. The 
results revealed that, at the lowest pH that theoretically can be found in the gizzard and 
according to some authors in the proventriculus 11, a partial reduction in the 
concentration of the phages phi F258E and phi F61E occurred and a complete reduction 
of the concentration of F78E was observed. It would be therefore expected that the in 
vivo oral administration of this last phage would result on its inactivation. Nevertheless, 
the experiments herein reported revealed the presence of phi F78E in all the emulsified 
organs, after oral administration. This apparent absence of deleterious effects of the low 
pH on the phages, might be explained by the diluting effect of water/ feed intake (ad 
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libitum intake) on the digestive system that could raise the pH in gizzard and 
proventriculus 30. Besides, it is important to emphasize that this phage was able to 
tolerate pH 3.5, a pH value more probably occurring during feed or water intake. 
Another important aspect to consider is the fact that phi F78E was the phage recovered 
in higher amounts, compared to the other three phages, after oral or spray 
administration. This phage had a commensal E. coli host strain in the intestine, and 
might have replicated there. This could be the reason why this phage reached and 
remained in the studied organs at higher titres for longer periods, being the only one that 
apparently reached the blood stream. Based on this result, it can also be speculated that 
there might be an advantage of administering a non-pathogenic bacterial host together 
with the phage in order to ensure its amplification in the gut. 
The ability of this phage to infect commensal E. coli strains can be advantageous in a 
phage therapy context because high internal titres of the phage are obtained. On the 
other hand by infecting commensal strains the phage might impair the flora equilibrium.   
The presence of phages phi F258E and phi F61E in the respiratory tract after oral 
administration cannot be explained by their penetration into the blood stream through 
the intestinal mucosa after reaching the duodenum, since they were not rescued by liver 
or spleen, filters against foreign organisms that enters the bloodstream. Thus, phages 
might have reached chickens’ lungs and air sacs probably due to the inhalation of 
aerosols or suspension droplets during the administration. Relative to phi F78E, aerosols 
might have been formed and breathed as well from the dust of the cages, where the 
concentration of this particular phage should be higher (due the presence of an intestinal 
host strain). Conversely to the other two phages, phi 78E was found in the liver and 
spleen when given orally to chickens, as well as in the duodenum, the segment of the 
small intestine with a higher absorption rate, indicating its absorption trough the 
intestinal mucosa. Some researchers 9, 13, 14, 32 reported that orally administered phages 
can reach the peripheral blood and migrate to the infection sites. The phage occurrence 
in the blood is also supported by several authors 9, 14, 23. 
Spray administration allowed all phages to reach the respiratory tract. This may be a 
promising route of administration allowing phages to reside in the tissues and 
membranes where the pathogenic bacteria are located. Huff et al. (2003) 19 also reported 
the presence of phages in the respiratory tract after aerosol administration. The fact that 
with this route of administration phages reached the chicken duodenum is probably due 
to the spray swallowing. This route allowed phi F78E to circulate in the bloodstream, 
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reaching all organs. Three hours after challenging the chickens intramuscularly, it was 
possible to find the three phages in all organs including lungs and air sacs. This is an 
important indicator for therapy, once phages can rapidly reach the target organs of 
infection for pathogenic E. coli. However, these results indicate that although phages 
rapidly disseminated in the animal organs (at least 3 h after challenge) reaching the 
infected tissues, they were quickly cleared by the chicken organism. In fact, all the 
phages were cleared from lungs after 10 h. So, for practical purposes, it can be 
hypothesized that in this particular case, phage therapy of respiratory infections is only 
efficient immediately after phage administration and the fact that phages would not 
confer protection against E. coli after 10 h might compromise their use as prophylactic 
agents. 
Whatever the route of administration, as expected, the phage dosage seemed also to be 
an important factor for phage therapy in vivo efficiency. Results suggest that the initial 
concentration of phages administrated intramuscularly, was directly proportional to the 
quantity of phages that reached the potentially affected organs (data not shown). A 
dose-dependence effect was reported by several authors in phage efficacy studies and 
modelling 5, 25, 33. 
Summarizing, phage dissemination into the chickens’ organs is highly dependent on the 
dosage and route of administration. The presence of commensal bacteria might also play 
an important role in phage spreading. Spray and oral phage administrations enables 
phages to reach the chickens respiratory tract and therefore can be consider important 
administration routes to control E. coli respiratory infections.  
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1. INTRODUCTION 
 
Escherichia coli (E. coli) is a commensal bacterium of chickens’ intestine. However, 
some E. coli strains, extra-intestinal pathogenic E. coli, are by their own, able to cause 
disease. In fact, avian pathogenic E. coli (APEC) possess specific virulence attributes 
causing invasive infections in poultry 35. The pathogenesis of APEC infections includes 
the colonization of the respiratory tract, the crossing of the epithelium and penetration 
into the mucosa of the respiratory organs, the survival and multiplication in the blood 
stream and internal organs, and the production of adverse effects and lesions on the 
chicken’s cells and tissues 13.  For these reasons, colibacillosis is a serious problem for 
poultry production. High morbidity and mortality levels and lesions on chicken’s tissues 
lead to carcass rejection at slaughter, causing important economic losses in avian 
industry 17. 
Antibiotics are being used to prevent and treat this disease, but as a consequence of its 
overuse, multiple antibiotic resistances are emerging. This fact constitutes a great public 
health threat worldwide 25. Moreover, few new active ingredients with novel 
chemotypes have entered the market over the past 30 years and new classes of agents 
are being developed 3. Bacteriophages (phages) are bacterial viruses, obligate 
intracellular parasites of bacterial cells. The ability of lytic phages to invade and disrupt 
bacterial metabolism causing the bacteria lysis and its own new progeny release, makes 
from these viral particles good candidates to perform as therapeutic agents. Phages are 
highly host specific, preventing the destruction of the most part of the healthy flora in 
the intestine, and they replicate inside the pathogenic bacteria, growing exponentially at 
the site of infection, where it is needed. Phages are harmlessness for animals and plants, 
and therefore, also for the environment 10, 32. 
In this work, in vivo trials were performed in order to determine the efficacy of three 
phages, phiF78E (Myoviridae), phi F258E (Siphoviridae) and phi F61E (Myoviridae) 
administered orally and by spray in treating chickens from severe colibacillosis.  
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2. MATERIALS AND METHODS 
 
2.1 Isolation of APEC strains  
 
Escherichia coli strains were isolated from poultry carcasses with colibacillosis, 
exhibiting typical post mortem lesions as perihepatitis, pericarditis, aerosacculitis and 
enteritis. Livers, spleen and lungs samples were collected from carcasses, emulsified in 
sterile saline solution (0.85% NaCl) and 0.1 ml of supernatant was plated in 
MacConkey agar, a selective medium for Gram-negative bacilli. Plates were incubated 
overnight at 37ºC. As E. coli, is a lactose fermenter, the specie confirmation of the 
isolates were conducted by selecting pink-red colonies from the referred media and 
using API E20 strips, according to manufacturer’s instructions (Bio-Merieux). E. coli 
isolates were stored in Nutrient Broth (Oxoid,) with 20 % glycerol, at -80 ºC. 
 
2.2 Bacteriophage isolation and amplification 
 
The bacteriophages used in this study, phi F78E, phi F258E and F61E were isolated 
from samples of sewage from Portuguese poultry houses, as described in Chapter II., 
section 2.4. Briefly, the isolation assay comprised an overnight incubation (37ºC) of 
these samples with the isolated E. coli strains, 3-4 h culture in Luria Bertani (LB) broth, 
the supernatant centrifugation at 9 000 × g for 10 min and filtration through 0.22 µm, 
and the searching for clear zones after spotting the resultant suspension over the 
respective bacterial strain lawn. The phage replication was performed by inoculating 10 
ml of 107 PFU/ml of each phage suspension in 100 ml of the respective host strain, 3-4 
h culture in LB broth, followed by an overnight incubation at 37ºC with shaking (120 
rpm). The resultant suspension was centrifuged at 9 000 × g for 10 min, filtered through 
a 0.22 µm membrane and stored at 4 ºC.  
The phage concentrations were determined based on the plaque assay method described 
by Adams (1959) 1. A volume of 100 μl of successive dilutions of the suspension of 
each phage, mixed with 100 μl of the host strain (3-4 h culture) and 3 ml of LB 0.6 % 
melted agar, was poured onto 1.5 % LB agar plates and incubated overnight at 37ºC.  
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2.3 Welfare, housing and handling 
 
The in vivo tests were performed in healthy growers (Rhode Island Red), acquired from 
a local poultry house. Preliminary experiments entailed the pathogenicity evaluation of 
the isolated E. coli strains sensitive to phages phi F78E, phi F258E and phi F61E. 
Subsequent trials were conducted to determine the efficacy of these three phages on 
treating chickens with experimentally induced colibacillosis. Phages were administered 
orally and by spray, in a single dose (administration routes discussed in Chapter IV), 
immediately after chickens have been challenged with an avian pathogenic E. coli 
suspension. 
All tests were designed and conducted in accordance with principles and specific 
guidelines of animal welfare of the Federation of European Laboratory Animal Science 
Associations (FELASA) 33, and based on the European Council Directive of 24 
November 1986 (86/609/EEC) guidelines, regarding the protection of animals used for 
scientific experimental purposes. In all the designed experiments, there was a great 
concern to minimize the number of animals used in the experiments. 
Chickens were housed in batteries, in two experimental rooms, with forced air 
exhaustion: the birds not exposed to phages were placed in a separated room (named 
phage-free room) from that of chickens subjected to phage treatment. Temperature and 
relative humidity were measured and controlled during the experiments, in order to 
ensure the optimal environmental conditions. A 5-days acclimation period preceded the 
challenging. Feed (commercial grower feed) and water were available for ad libitum 
consumption. The birds were weighted at the day of arrival and at the beginning of the 
experiment.  
The efficacy of the treatments was evaluated based on mortality, morbidity and severity 
of the colibacillosis lesions 34. Chickens that died during the challenging period, and the 
ones euthanized at the end of the trial through isoflurane (IsoFlo®, Abbott) inhalation 12 
were submitted to the post mortem examination. The severity of the lesions was 
evaluated and scored as follows: 1- no macroscopic lesions or thickening and opacity of 
the inoculated air sac; 2- non severe lesions in the internal organs, not interfering in 
carcass quality; 3- severe and generalised colisepticemia injuries, as fibrinous 
aerosaculitis, pericarditis and perihepatitis; 4- death before euthanasia. The pathology 
score of each group was calculated: (∑ (number of birds with the same score × score)) / 
total number of birds.  
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Before the beginning of the trials, chickens were monitored for the presence of other 
phages active against the challenging E. coli strains. For that purpose, feces were 
collected from each battery, emulsified in LB broth, inoculated in a 3-4 h grown culture 
of the selected APEC strain, and incubated at 37ºC overnight with shaking (120 rpm). 
After centrifugation at 9 000 ×g for 10 min and filtration through 0.2 µm, the 
suspension was spotted on the bacteria lawns (LB agar), incubated at 37ºC overnight, 
and checked for clear zones. This procedure was repeated daily in the phage-free room. 
The screening of phage-sensitive commensal enterobacteria was also performed. 
Cloacae swabs were collected, seeded in several MacConkey agar plates and incubated 
at 37ºC. Eight to ten pink colonies were picked from each plate, separately incubated in 
10 ml of LB broth at 37ºC for 3 to 4 h, and each one was spread in a lawn for phage 
sensitivity test: 10µl of phage were dropped on plate bacteria lawns, and incubated at 
37ºC overnight. Plates were then checked for clear zones. 
 
2.4 In vivo pathogenicity tests of  phage-sensitive E. coli strains 
 
i) Phi F61E-sensitive strain  
The in vivo virulence of a phi F61E-sensitive strain, H161E, was evaluated. Six-weeks-
old chickens with 332.9 g Body Weight (BW) in average were divided in two groups of 
four. One of the groups was challenged with E. coli (0.2 ml of a bacterial suspension of 
2.3x108 CFU/ml) injected in the chickens’ left air sacs and the other received LB broth 
as a placebo, by the same way.  
The euthanasia and post mortem examination was carried out 5 days after inoculation.  
 
ii) Phi F258E and phiF78E-sensitive strains 
The same procedure described for the phi F61E-sensitive strain, H161E, was performed. 
However, in this case chickens were challenged with the E. coli strains using two 
different ways: i) injections of the bacterial suspensions in the chickens’ left air sac; ii) 
inoculation directly into chickens’ trachea, through a syringe fitted with an adapted 
blunt ended needle (intratracheal inoculation). A volume of 0.2 ml (5.0×108 CFU/ml) of 
each bacteria suspension was used in both ways. 
In this test, 8 weeks-old chickens, weighting in average 732.5 g (BW) were housed in 
batteries, in 14 groups of four chickens each. Two of the groups received sterile LB 
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broth as a placebo intratracheally and intra sacs, respectively. The other groups 
(challenged groups) were inoculated with the six E. coli strains (H280E and H856E, 
both F258E-sensitive, and H757E, H924E, H839E and H1094E, phi F78E-sensitive) by 
each of the two routes of infection. 
The euthanasia and post mortem examination was carried out 5 days after inoculation.  
 
2.5 In vivo evaluation of phages efficiency to treat colibacillosis  
 
i) PhiF61E 
In this study, 25 chickens of 6 weeks-old, weighing 332.9 g (BW) in average, were 
divided in three groups: two groups of 11 birds were injected in the left air-sac with 0.2 
ml, 1x108 CFU/ml, of a H161E suspension; one of these groups received orally 1ml of 
3.3x107 PFU/ml of a phi F61E suspension and 1ml by spray. One group of 3 birds had 
sterile LB broth as placebo by intra-sacs injection. The euthanasia was performed 7 days 
after challenging.  
 
ii) Phi F258E alone and in combination with antibiotic 
Nine weeks-old chickens with 767.1g (BW) in average were used. The selected strain to 
challenge the birds, H280E was submitted to an antibiogram (performed as described in 
Chapter II) and the Amoxicillin (AML) was the selected as the active agent. Forty seven 
chickens were housed and divided in five groups: four groups of 11 chickens were 
challenged with H280E (0.2 ml of 7.5x108 CFU/ml) by intratracheal inoculation, 
whereas one group of 3 chickens was used as the negative control, receiving sterile LB 
broth, also intratracheally. One of the infected groups was not treated whereas the other 
three groups were treated, respectively, with phages, with an antibiotic and with phages 
and antibiotic simultaneously. The antibiotic treatment was performed by diluting AML 
(0.2 g/l) in the drinking water (this is the usual antibiotic treatment procedure) during 
the whole experiment. The phage treatment was performed by administrating phi F258E 
(5.7x107 PFU/ml) orally and by spray (1 ml by each route). The treatment with phage 
and antibiotic was performed by giving AML (0.2 g/l) in the birds’ drinking water, in 
the same described conditions, and phages orally and by spray. 
The euthanasia was carried out 7 days after challenging.  
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iii) Phi F78E at different titres alone and in combination with antibiotics 
(a) Low phage titre suspension 
In this trial, the phi F78E efficacy to control APEC infections was also determined in 
association with an antibiotic. The challenging E. coli strain selected above, H839E was 
submitted to an antibiogram (performed as described in Chapter II) and the active agent 
used was the AML. A total of 40 growers of 12 weeks-old weighing 1055.1 g, were 
randomly divided in groups and placed in batteries. Four groups of 9 birds were 
challenged by injection with 0.2 ml of a 3-4 h grown culture of E. coli containing 
5.0×108 CFU/ml, in the left air-sac. Immediately after being challenged, two of the four 
groups were treated with a suspension of 5.2×107 PFU/ml phi F78E, orally (1ml) and by 
spray (1ml). One of these two groups received as well, 0.2 g/l AML in the drinking 
water, during the whole experiment. The third challenged group was treated only with 
the antibiotic (same prescription). A group of 4 birds was set as the negative control, 
receiving sterile LB broth as a placebo, injected in the air sacs. 
 
(b) High phage titre suspension 
In the subsequent trial, the concentration of phage administered was 1.5×109 PFU/ml. A 
total of 28 chickens of 10 weeks-old, weighting in average 883.9 g (BW), were divided 
in three groups and placed in batteries. Two groups of 12 chickens were challenged, as 
previously described, with 0.2 ml of a 3-4 h grown culture of 5.0×108 CFU/ml H839E 
by intra-sacs injection. One of the groups was treated with 1 ml of phi F78E orally and 
1 ml by spray. The negative control, comprised of 4 birds was treated as in (a). In both 
trials, the euthanasia and post mortem examinations were performed 7 days after being 
challenged with E. coli.  
 
iv) Post mortem screening for the presence of host resistant strains  
At the post mortem examination of each efficiency trial, infected livers were collected 
from the phage-treated groups. The organs were emulsified, separately, in LB broth. A 
volume of 0.1 ml of the supernatant was plated in MacConkey agar. Plates were 
incubated at 37ºC overnight. Pink-red colonies were picked, sowed in the same selective 
media and incubated at 37ºC overnight, being this procedure repeated three more times.  
In each of the experiments, in order to test if the strain isolated from the carcasses 
remained sensitive to the respective infecting phage, about 10 pink-red colonies were 
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picked from the previously incubated MacConkey agar plates, inoculated separately in 
0.6 % LB agar, and poured onto the wells of a 24-well microplate. This procedure was 
performed in duplicate and 5 µl of phage suspension were dispensed in each bacteria 
lawn. The original E. coli strain was used as positive control. 
 
2.6 Statistical analysis 
 
A two-sided Student´s t-test was used, with a significance level of 5% and a statistical 
power of 90% (α = 0.05 and π = 0.90). The experimental unit was considered to be the 
chicken. The estimation of the  number of experimental units needed for was based on 
Beyen et al. 7 statistical assumptions, in which the sample size was function of the 
difference considered meaningful between groups from a physiological point of view, 
expressed as multiples of the standard deviation that was estimated from an  anticipated 
individual variation ((µ1-µ2)/σ).  
The individual variation was estimated previously as 10% in average, and the 
meaningful difference between groups (P>0.05) was variable according to the trial.  
In the E. coli pathogenicity tests, 30% of differences were considered meaningful 
between groups’ results, and thus, 4 experimental units per group were used. In the first 
phage efficiency trial, to get 20% of differences between group’s responses as 
meaningful, it was necessary to use at least 7 experimental units per group and in the 
second phage efficiency tests (in which the dose of treatment was increased), a 
minimum of 11 experimental units allowed to compare groups with 15 % of accepted 
biological difference.  
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3. RESULTS 
 
3.1 In vivo pathogenicity tests of phage-sensitive E. coli strains  
 
i) Phi F61E-sensitive strain  
In vivo virulence tests of H161E injected in chickens’ left air sacs resulted in no 
mortality recorded in the challenged group. The morbidity was 100% and the pathology 
score 2.3 (data not shown). This strain was used in the phage phi F61E efficiency trials.  
 
ii) Phi F258E-sensitive strains 
This in vivo experiment, allowed the selection of the most pathogenic phi F258E-
sensitive E. coli strain and the challenge route able to induce colibacillosis in chickens. 
Results are illustrated in Figure V.1. In the group injected intra-sacs with H280E, all the 
chickens got sick, scoring 3.25. When chickens received the bacterial suspension in the 
trachea, neither the morbidity nor the pathology score were significantly lower than in 
the group injected in the air-sacs with the same suspension (P<0.05) (Figure V.1A and 
C). In both groups infected with H280E, the mortality was 50% (Figure V.1B). 
Chickens challenged with H856E by air-sac injection, presented a higher percentage of 
morbidity compared to chickens inoculated intratracheally. Nevertheless, the severity of 
lesions was not statistically different between birds infected by these two routes. 
Mortality caused by this strain was reported by none of the referred routes. Chickens 
infected with the placebo didn´t get any injuries. 
According to these results, H280E seemed to be more virulent than H856E, so, this 
strain was selected to induce colibacillosis in the phage efficiency trials. Concerning the 
challenging route, after H280E intra-sacs injection birds got prostrated and two birds 
died in the inoculation day (data not shown), suggesting that the infection was rapidly 
spread and installed. Conversely, the intra-tracheal inoculation led to a less severe 
infection. In this case, bird prostration only occurred from the second day on, and the 
first bird died in the 3rd day. Based on these results, intra-tracheal challenging route was 
used to assess phage efficacy because it reproduces in a more realistic way the 
progression of the infections in aviaries. In fact, since colibacillosis doesn´t occur in all 
flock simultaneously or with the same level of severity (the morbidity varies and 
mortality ranges from 5 to 20% 22), birds cohabit in different stages of infection, from 
earliest to systemic stages. Consequently, phage efficacy on therapy could vary. It might 
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thus be important that in experimental conditions, birds develop the infection in diverse 
stages. 
 
A.       
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C.  
 
Figure V.1 Morbidity (%) (A.), mortality (%) (B.) and pathology scores (C.) observed 
in each group of chickens (n=4) challenged with APEC strains, H280E and H856E, and 
with sterile LB broth (placebo), by intratracheal inoculation ( ) or injected in the left air 
sac ( ).  Scores - 1: no injuries; 1 to 2: non severe lesions of colibacillosis; 2 to 3: 
generalised lesions of colibacillosis; 3 to 4: acute colisepticemia. Error bars indicate a 
meaningful difference of 30%. 
 
iii) Phi F78E-sensitive strains 
Injuries caused by the APEC strains, namely H757E, H839E, H924E and H1094E, in 
challenged chickens were registered and scored, after post mortem examination (Figure 
V.2).  
A.  
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
H280E H856E Placebo
Sc
or
e
Pathology score
0
20
40
60
80
100
H757E H924E H839E H1094E Placebo
%
  
Morbidity
The bacteriophage therapy for colibacillosis in poultry 
 
 95  
B.  
 
C.  
 
Figure V.2 Morbidity (%) (A.), mortality (%) (B.) and pathology scores (C.) observed 
in each group of chickens (n=4) challenged with APEC strains, H757E, H924E, H839E, 
H1094E, and sterile LB broth (placebo), by intratracheal inoculation ( ) or injected in 
the left air sac ( ). Scores - 1: no injuries; 1 to 2: non severe lesions of colibacillosis; 2 
to 3: generalised lesions of colibacillosis; 3 to 4: acute colisepticemia. Error bars 
indicate a meaningful difference of 30%.  
 
Regarding the morbidity and the lesions scores, no statistical difference (P>0.05) 
occurred among the groups of animals challenged by intra-sacs injection with H757E, 
H924E and H839E strains, being detected in most of the birds severe and generalised 
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lesions consistent with colibacillosis. Conversely, when the birds were challenged with 
H1094E, no lesions were detected in carcasses and the scores were similar to the 
negative control (P<0.05). 
When inoculated in the trachea, the strains H757E and H839E caused higher morbidity 
in chickens than H924E and H1094E, being the lesions caused by H839E the most 
severe (P<0.05). Particularly, H924E and H839E originated more illness when 
administered in the air sacs than in the trachea (Figure V.2 B.). Concerning mortality, 
only the strain H839E injected in the air sacs caused chickens deaths (Figure V.2A.). 
Taking into account these results, it seemed that the most pathogenic E. coli strains 
tested was the H839E, and the air sac injection the most effective way of causing a 
severe infection. These results were considered in the subsequent experiments.  
 
3.2 In vivo evaluation of phages efficiency in treating colibacillosis 
 
i) Phi F61E 
The microbiological control of the birds at housing revealed no phage particles active 
against the inoculated host and no phi F61E-sensitive strains were found in the 
chickens’ feces. The daily phage screening in the “phage-free” experimental room 
revealed a total absence of this phage during the trials.  
Results from this experiment are presented in Figure V.3. The treatment with phi F61E 
slightly decreased the morbidity (P>0.05) from 100% to 72.7%. However, there were 
no significant differences in the lesions scores between the treated and the untreated 
groups, and mortality wasn’t reported in none of them (data not shown). Birds from 
negative control did not exhibit any injuries. In these conditions, this phage was not 
considered to be efficient in treating the induced colibacillosis. 
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A.                                                                        B. 
Figure V.3 Morbidity (%) (A.) and pathology scores (B.) obtained for each group of 
chickens (n=11). Groups: phi F61E+ H161E ( ) - challenged with H161E and treated 
with phi F61E; H161E ( ) - challenged with H161E. Scores - 1: no injuries; 1 to 2: non 
severe lesions of colibacillosis; 2 to 3: generalised lesions of colibacillosis; 3 to 4: acute 
colisepticemia. Error bars indicate a meaningful difference of 15%.  
 
ii) Phi F258E  
In this trial, the microbiological control of the birds at housing revealed absence of 
phage particles active against the inoculated host and no phi F258E-sensitive strains 
was found in the chickens’ feces. The daily phage analysis in the “phage-free” 
experimental room was always negative.  
Mortality and morbidity, as well as lesions scores recorded in each group are present in 
Figure V.4. (A and B). 
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A.  
B.  
Figure V.4 Morbidity and mortality (%) (A.) and pathology scores (B.) obtained for 
each group of chickens (n=11): Groups: phi F258E+H280E ( ) - challenged with 
H839E and treated with phi F258E; AML + H280E ( ) - challenged with H280E and 
treated with Amoxicillin; phi F258E+AML+H280E ( ) - challenged with H280E and 
treated with phi F258E and Amoxicillin; H280E ( ) - challenged with H280E. Scores: 
1- no injuries; 1 to 2- non severe lesions of colibacillosis; 2 to 3- generalised lesions of 
colibacillosis; 3 to 4: acute colisepticemia. Error bars indicate a meaningful difference 
of 15%.  
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In this experiment, no significant differences (P>0.05) in mortality, morbidity or 
pathology scores were obtained between the untreated group and the group treated with 
phi F258E. In the groups treated with AML and with the association of the antibiotic 
and the phage, the mortality and morbidity were significantly lower than in the other 
groups (P<0.05). In the former group these parameters were still lower than in the latter. 
Carcasses from the group treated only with the antibiotic showed the less severe lesions. 
Thus, from these results it can be inferred that phi F258E was not effective in 
controlling the infection with H280E.  
 
iii) Phi F78E 
(a) Low phage titre suspention 
The microbiological control of the birds at housing revealed no phage particles active 
against the inoculated host and no phi F78E-sensitive to E. coli strains present in the 
chickens’ feces. The daily phage presence control in the “phage-free” experimental 
room revealed a total absence of this phage during trials.  
This in vivo efficiency experiment was performed by infecting chickens with 5×106 
CFU/ml H839E and immediately after, by administering 5.2×107 PFU/ml phi F78E 
orally and by spray, with and without the simultaneous administration of AML in the 
drinking water . The pathology scores and the morbidity and mortality recorded in this 
experiment, for the four challenged groups, are present in Figure V.5. Chickens from 
the negative control did not develop any lesion detectable at the post mortem 
examination. 
A.  
0
20
40
60
80
100
Morbidity Mortality
%
Phages Efficiency to Control E. coli Infections in Chickens  
 
 100  
B.  
Figure V.5. Morbidity and mortality (%) (A.) and pathology scores (B.) obtained for 
each group of chickens (n=9). Groups: phi F78E+H839E ( ) - challenged with H839E 
and treated with phi F78E; AML+H839E ( ) - challenged with H839E and treated with 
Amoxicillin; phi F78E+AML+H839E ( ) - challenged with H839E and treated with phi 
F78E and Amoxicillin; H839E ( ) - challenged with H839E. Scores: 1- no injuries; 1 to 
2- non severe lesions of colibacillosis; 2 to 3- generalised lesions of colibacillosis; 3 to 
4: acute colisepticemia. Error bars indicate a meaningful difference of 20%. 
 
No meaningful differences (P<0.05) were observed between groups, relatively to the 
scores of birds lesions and the morbidity (Figure V.5A and V.5B). The mortality 
percentage did not differ between the groups phi F78E+H839E, phi 
F78E+H839E+AML and H839E (P>0.05), being however in these cases statistically 
higher (P<0.05) than in the group AML+H839E (Figure V.5 B). In all groups, mortality 
occurred in the inoculation day.  
For these trial settings, neither the phage preparation nor the antibiotic (acting 
individually or in association) was efficient in treating chickens from the infections 
caused by E. coli.  
 
(b) High phage titre suspension 
The results from the microbiological control at housing and the daily phage screening in 
the “phage-free” room were identical to those previously described. 
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In this  in vivo trial, in which the concentration of phage administered was 1.5×109 
PFU/ml, the pathology score, the morbidity and the mortality were significantly lower 
(P<0.05) in the group phage-treated than in the untreated group (H839E) (Figure V.6A). 
Lesions found in carcasses were also less severe in the phage-treated group (Figure 
V.6B). 
 
 
 
 
 
 
A.                                                                                          B. 
Figure V.6 Morbidity and mortality (%) (A.) and pathology scores (B.) obtained for 
each group of chickens (n=12). Groups: phi F78E+H839E ( ) - challenged with H839E 
and treated with phi F78E; H839E ( ) - challenged with H839E. Scores: 1- no injuries; 
1 to 2- non severe lesions of colibacillosis; 2 to 3- generalised lesions of colibacillosis; 3 
to 4: acute colisepticemia. Error bars indicate a meaningful difference of 15%. 
 
With this highly concentrated phage suspension, a decrease, in average, of 25.0% on 
chickens’ mortality and of 41.7% on morbidity was obtained.  
In the negative control group, no chicken died and no lesions were detected in the post 
mortem analysis. 
 
iv) Post mortem screening for the presence of host resistant strains  
In all the phage-treated groups in study, the E. coli isolated from chickens receiving the 
phage preparations remained sensitive to the phages even after being in contact with it 
in the organism. 
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   4. DISCUSSION 
 
It has been suggested that phages might be able to reduce the densities and of 
dissemination of the infecting populations of bacteria to levels at which they are 
possible to be controlled by the host immune system 21. Furthermore, by replicating in 
the infected areas, phages shall be able to control localized infections that are relatively 
inaccessible via the circulatory system as, for example, the air sacs in chickens. 
Theoretically, if a bacteriophage reaches the site of a bacterial infection, it should be 
effective in eliminating the infection 20 10, 11, 27, 32. These attributes make phages 
powerful antimicrobials alternatives. This idea is shared by several phage researchers 
who postulate that these viral particles, as antibiotics, are effective in treating bacterial 
diseases. Indeed, successful trials are being reported, with phages conferring high 
protection levels against infections 4, 6, 8, 15-19, 24, 28-31. 
In this work, the in vivo efficiency of phi F68E, phi F78E and phi F258E in treating 
chickens with colibacillosis was evaluated. As previously described (Chapter II) a 
cocktail of these phages are able to cover about 70.5% of the most common APEC 
strains causing colibacillosis in Portuguese poultry farms. Phages were tested 
independently in order to evaluate its individual performance. 
Prior to the in vivo phage efficacy trials, preliminary experiments were conducted in 
order to select the strain or strains and the challenging routes able to cause chickens 
colibacillosis. For this purpose, chickens were submitted to intra-sacs or intratracheal 
injections of APEC strains sensitive to the phages, and mortality, morbidity and severity 
of lesions were recorded. Typical signs of colibacillosis are caracterised by multiple 
organ lesions, typically pericarditis, aerosacculitis, perihepatitis and septicemia 2, 14. 
Apparently all strains except one, H1094E, caused typical symptoms of collibacilosis. 
However some of them did not cause any mortality. The exception was H280E and 
H839E. Chickens infected with H161E, H280E and H839E exhibited clear signs of 
colibacillosis, so, these strains were selected to be used in the phi F61E, phi F258E and 
phi F78E efficiency experiments, respectively. Two inoculation routes were tested, and 
for the most virulent strains, intra-sacs injections induced a rapid and severe disease. 
Conversely, intratracheal inoculation seemed to promote a more gradual evolution of 
the infection which is more close to the real conditions.  
It was curious to notice that, despite all the in vivo tested E. coli strains are isolates of 
chickens suffering from colisepticemia, they promoted different levels of pathological 
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signs. Those variations might happen, since the infections occurring in the natural 
environment might be often aggravated by extrinsic and intrinsic conditions affecting 
birds, as the exposure to other infectious agents, the levels and duration of exposure to 
bacteria, the route of infection, the vulnerability of the management conditions, among 
others 26. Those are important variables affecting birds’ susceptibility in Nature that are 
not possible to mimic in controlled experimental rooms.  
In the in vivo phage efficacy trials, phi F61E was able to reduce the morbidity, in 
average, 27.3%. However the severity of the lesions in carcasses observed on the post 
mortem analysis were not significantly different from the control group. This fact might 
indicate that some of the birds that effectively got sick in the phage-treated group had 
more severe pathological signs in organs than in the untreated group. So, it might be 
speculated that, at in this experimental conditions phages were only able to treat the 
chickens that were in an early stage of the infection.  
Phage phi F258E was ineffective in controlling the induced E. coli infection. 
Conversely, the antibiotic significantly decreased the morbidity and mortality, as well as 
the pathology scores. It must be noticed that, while the antibiotic was being 
continuously administered for the whole experiment, the phage was given as a single 
dose, only at the beginning. 
Respecting to the phi F78E efficiency performance, when it was administered at 107 
PFU/ml, this phage was not able to control the infection. No meaningful differences 
were noticed between morbidity and pathology scores in the untreated and in the phage-
treated groups. In this case, the antibiotic was also ineffective in controlling the disease. 
These results might be explained by the severity and rapid progression of the infection 
(in groups challenged with H839E, mortality occurred in the day of the inoculation) and 
on the other hand, with an administered phage concentration which was probably too 
low to control such a severe infection.  
It is important to reiterate that, unlike experimental conditions, in natural-occurring 
infections the bacteria transmission happens gradually and horizontally from one 
chicken to another, and birds are not synchronized at the same stage of infection 19. 
Therefore, despite these unsuccessful results, it might be speculated that the tested 
phage titre could be efficient in treating natural colibacillosis, by controlling the earlier 
stages of the infection and avoid the progressive transmission to the flock.  
The importance of the phage administered concentrations was demonstrated in the in 
vivo phage performance evaluation. Experiments have been shown that the effectiveness 
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of therapy with phages highly depends whether the phage titre administered provides or 
not the sufficient number of particles to the site of the infection 15, 27, 17, 20. Moreover, it 
is reported that in a systemic infection, the treatment efficacy would be improved by 
ensuring that sufficiently large numbers of phage are available in the blood stream. In a 
previous study (Chapter IV), we have demonstrated that phi F78E at 107 PFU is able to 
reach the lungs and air sacs when administered orally and by spray, so, reinforcing what 
was said above, the amount of phage was not probably enough to control such a severe 
infection.  
Indeed, a phage concentration of 5.2×107 PFU/ml was not efficient to control the 
infection, but higher concentration of phage (1.5×109 PFU/ml) was able to decrease 
25.0% the mortality and 41.7% the morbidity of the treated birds. 
Encouraging results were also obtained in other works describing phage administration 
by an aerosol spray, in which significant although not complete protection to chickens 
form severe colibacillosis was obtained 15, 17, 19. Huff et al. (2005) reported that, once the 
infection become systemic, the spray doesn´t seem to be very effective on treating the 
disease 19. The protecting capacity of phages after oral administration has been 
documented in other species 5, 9, 23, 24. 
It must be stressed that some differences on mortality and morbidity (caused by the 
same strain) between control groups from different experiments were noticed. This 
might be due to differences on chicken’s age, between experiments. Nevertheless, for 
each trial, conditions were uniform, and chickens under study were always from the 
same batch. Thus comparisons between groups in the same trial are considered to be 
trustfully.  
 Overall, the results of the phage in vivo performance, demonstrated that the efficacy of 
phage treatment might be dosage dependant. The failure of some of the phage 
treatments reported is probably due to the fact that, phages administered orally and by 
spray in a low dosage, were not able to control systemic infections. In fact, 
colibacillosis was artificially induced by inoculating high amounts of APEC strains in 
the bird’s respiratory tract. When phages were administered, the animals were suffering 
already from a severe E. coli infection and only a high phage dosage was able to control 
the infection.    
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1. INTRODUCTION 
 
Escherichia coli are part of the common microbial flora of the poultry intestine. 
However, despite most of the isolates are harmless, about 10 to 15 % of the serotypes 
are pathogenic 1, the avian pathogenic E. coli (APEC), causing systemic disease in 
poultry (avian colibacillosis) 4. This infection is responsible for important economic 
losses in the poultry industry worldwide, due to lowered production, high treatment 
costs, carcass rejection at processing and mortality 16, 27. Losses occur at all ages. 
Depending on the virulence grade of the strain, on host susceptibility or influence of 
external predisposing factors, the infection manifests as an initial septicemia, followed 
by either rapid death or by a diverse display of lesions as perihepatitis, aerosacculitis 
and pericarditis, among others 1. Morbidity varies, in average, between 5 to 20% in 
intensive raised flocks 13. The antibiotic therapy is being used to control colibacillosis, 
however a significant increase in drug-resistant strains of E. coli has also become a 
problem in the poultry industry 17. In fact, the use of antibiotics is considered the most 
important factor promoting the emergence, selection and dissemination of antibiotic-
resistant microorganisms 26, limiting its own therapeutic effectiveness.   
The efficacy of bacteriophage therapy has been reported by numerous authors. In vivo 
confined experimental trials have been performed to establish the proof of principle of 
bacteriophage therapy to treat different animals against different types of bacteria 6-11, 14, 
15, 19-24. However, in vivo confined trials do not reproduce all real condition that 
influences the outcome of any antimicrobial therapy.  
In the present manuscript the efficacy of phage therapy in treating broiler chicken flocks 
from colibacillosis is reported. A phage cocktail was administered to flocks naturally 
infected with E. coli and refractive to antibiotherapy. 
 
2. MATERIALS AND METHODS 
 
2.1 Therapeutic phage cocktail composition 
 
Bacteriophages were isolated from samples of poultry sewage, collected randomly from 
Portuguese poultry houses (Chapter II). Three genetically different virulent phages, phi 
F78E, phi F258E and phi F61E, active against 70.5% of APEC strains, were selected to 
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compose a therapeutic cocktail. Taxonomically, phi F78E and phi F61E seemed to be 
16-19 type phages, belonging to Myoviridae family and phi F256E, a T1-like, 
Syphoviridae phage. 
The phage cocktail used in this study was composed by 5.0x107 PFU/ml of each phage, 
in LB broth 20% NaCl. The phage production was performed by inoculating 50 ml of 
107 PFU/ml of each phage suspension in 500 ml of the respective host strain (3-4 h 
culture in LB broth) followed by an overnight incubation at 37ºC with shaking (120 
rpm). The resultant suspension was centrifuged at 9 000 × g for 10 min, filtered through 
a 0.22 µm membrane and stored at 4 ºC. In order to determine the phage concentration, 
a volume of 100 μl of successive dilutions of the suspension of each phage, mixed with 
100 μl of the host strain (3-4 h culture) and 3 ml of LB 0.6 % melted agar, was poured 
onto 1.5 % LB agar plates and incubated overnight at 37ºC. Distinct phage plaques 
detectable in the higher dilutions indicated the phage concentration. 
 
2.2 Large scale experiments  
 
E. coli infected flocks with high mortality rates even after antibiotic treatment, were the 
experimental units of these experiments (n=11). Dead chickens from each of these 
flocks was submitted to post mortem analysis, and after confirmation that death 
occurred due to colisepticemia, through lesions macroscopic evaluation (perihepatitis, 
pericarditis, aerosacculitis, enteritis...), samples of infected organs - livers, spleen and 
lungs - were collected from carcasses. Those samples were emulsified (1:10 (v/v)) in 
sterile saline solution (0.85% NaCl) and 0.1 ml of supernatant was plated in 
MacConkey agar, a selective medium for Gram-negative bacteria. Plates were incubated 
overnight at 37ºC and, pink-red colonies (indicative of E. coli presence) were selected. 
API E20 strips (Bio-Merieux) were used to specie confirmation of the isolates.  
For each isolated E. coli, in vitro phage lytic tests were performed, by spotting 10 μl of 
the cocktail suspension over the respective bacterial lawn in LB agar. Plates were 
incubated overnight at 37ºC. Clear zones indicated phages in vitro efficacy to lyse the 
bacteria causing the infection, in the respective flock. In these cases, the phage mixture 
was administered to all flock, as a single application. A volume of 500 ml for 10 000 
birds was prescribed: half of the dose was diluted in the drinking water to be consumed 
in half day, and the other 250 ml were administered by fine drop spray , by adding a 
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volume of 500 ml of water for each 1000 birds. The water used in this trial was free of 
disinfectants or other phage inhibitors. Mortality was recorded at the beginning of the 
trial, and for three weeks on. 
 
2.3 Statistical analysis 
 
A two-sided Student´s t-test was used to compare groups, with a significance level of 
5% and a statistical power of 90% (α = 0.05 and π = 0.90). The estimated number of 
experimental units needed to the trials (the flocks) were obtained based on Beyen et al. 2 
statistical assumptions. The estimated coefficient of variation between flocks was 10% 
and the difference considered meaningful between groups was 15%.  
 
3. RESULTS 
 
E. coli strains isolated form 11 flocks of broiler chickens (Rhode Island Red) with 7 
weeks-old in average, were shown to be in vitro sensitive to the prepared phage 
cocktail. Flocks had between 5 000 and 10 000 birds. The mortality before and after the 
phage cocktail administration was registered and is presented in Figure VI.1. The 
infection was considered to be controlled once the mortality was 0.5% or less (usual in 
healthy flocks), and in most cases, reaching this condition, no further data was 
collected.  
One week after the cocktail administration, the mortality was controlled in five flocks 
(≤0.5%). In the following week, one more flock achieved the regular levels of mortality, 
and at the third week, all the flocks except one, were controlled for colibacillosis. The 
exception was relative to one case (indicated with an arrow in Figure VI.1), in which the 
mortality decreased consistently since phage administration, from 1.52% to 0.68%. No 
recidivism in the mortality rate was observed in any flock until slaughter.     
One case study of a broiler’s flock (Cobb) was also studied under the described 
conditions, and results showed that, besides a mortality decrease during the experiment 
(from 0.6 to 0.08 %), the rejections at slaughter were reduced as well with the phage 
administration, from 4.8 % to 1.82 % (data not shown). 
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Figure VI.1 Mortality rate (%) measured in 11 E. coli naturally infected flocks, 
previously treated with antibiotics. Records were taken at the phage administration and 
repeated weekly, for 3 weeks: week before phage administration ( ); 1st week ( ); 2nd 
week ( ); 3rd week ( ).  Error bars indicate a meaningful difference of 15 %.   
 
4. DISCUSSION 
  
A three phage cocktail was used in this study as a therapeutic product to control 
colibacillosis in poultry. Many authors recognize benefits on having different phages on 
the same product, enlarging the lytic spectra and delaying the resistances occurrences to 
phages 3, 5, 10, 18, 21, 25.  
In this work, a low titre phage product was administered, in a single application, orally 
and by spray to flocks naturally infected with pathogenic E. coli, and results showed a 
mortality reduction in no more than three weeks. The gradual decrease revealed that the 
number of chickens that reached acute septicaemia and consequently died diminished 
and this might be due to the phages action, by destroying bacteria on early stages of 
infection. Also the probability of bacteria propagation from bird to bird might have been 
prevented. So, despite the recognized importance of a high phage concentration for 
successful therapy12, it is possible that, in natural occurring infections in which chickens 
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are in different stages of colibacillosis evolution, a lower titre phage product becomes 
effective as well. The product must, nevertheless, be administered as soon as possible 
after the infection diagnosis. 
The administration of a low phage titre is also advantageous since it is more feasible to 
produce large volumes of low concentrated phage suspensions. 
As a main conclusion it can be said that phages are able control colibacillosis by 
avoiding chickens’ losses before severe lesions or septicemia occur, and that they might 
be able to act therapeutically in early stages of infection. This last assumption can 
explain the potential decrease of carcasses rejection at slaughter.  
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FINAL CONCLUSIONS 
 
The studies presented in this thesis were designed aiming the development of a phage 
product, constituted by no more than five phages, to be used as an antimicrobial 
alternative in the poultry industry. This product showed to be able to control 
colibacillosis propagation within flocks and consequently, the evolution of this infection 
into colisepticemia. The work was conducted in collaboration with Controlvet- 
Segurança Alimentar S.A., a company that provides consulting services for the poultry 
industry, mostly based on microbiological data obtained from samples recovered from 
the field. This company identified the need of having alternatives to the antibiotics, and 
proposed the analysis of the effectiveness and feasibility of phage therapy on the poultry 
daily management.  
Bacteriophages were isolated from aviaries. The cocktail was expected to cover the 
widest range of E. coli strains with the minimum quantity of phages, and based on this 
assumption, the in vitro lytic spectra evaluation was performed. Three phages were 
selected for further studies, phi F61E, phi F78E and phi F258E. Taxonomically, they 
belong to the Caudovirales order. Two of them, phi F61E and phi F78E, belong to the 
Myoviridae family and are 16–19 phages (T4-like). Phi F258E is a Syphoviridae , and 
looks like T1. All of them are genetically different and apparently lytic (according to 
their morphology). Nevertheless, this assumption was confirmed by a stress-induction 
prophage release test.  
In vivo experiments were designed and carried on in confined experimental rooms, in 
order to assess the safety and efficacy of this three-phage product. For the experimental 
designs, the coefficient of variation between the experimental units 1 (Rhode Island Red 
chickens) was estimated based on the weight of commercial growers (data not shown). 
This parameter was set to be 10%.  
In a first trial, after producing the phage cocktail in a concentration of 108 PFU/ml, the 
quantity of endotoxin (LPS) present in the suspension was determined. Chickens were 
injected (i.m.) with the phage lysate. As no abnormal behavior was detected in chickens, 
like prostration or reluctance to move, depression, somnolence, loss of thirst and 
appetite or loss of weight, except in the day of the inoculation, and as no toxicity effects 
were notice in organs at post mortem examination, the product was considered to be 
safe for the birds. In a following experiment, the best administration mode and 
concentration was identified. Two of the tested routes, the oral and the nasal, showed to 
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be efficient in delivering the phages to the target organs involved in colibacillosis and 
furthermore the bloodstream. These routes are very feasible for the management of 
flocks with large number of birds. Concerning phage concentration, (106 PFU/ml, 107 
PFU/ml and 108 PFU/ml), 107 PFU/ml seemed to be enough to provide phages to the 
organs. Besides, it might be economically viable for the scale up production. 
In the last in vivo trial, the aim was to test the phages efficiency on treating chickens 
challenged with APEC strains. The phages were tested separately. Preliminary 
experiments were designed to select the most suitable phage-sensitive APEC strain to 
infect chickens, and to determine how the birds should be inoculated. The phages were 
administered orally and by spray in a concentration of 107 PFU/ml, as suggested by the 
results of the previous experiment. The parameters evaluated during the trial were the 
mortality and morbidity, as well as the pathology score of the organs observed post 
mortem. The results of this trial showed that none of the 3 phages was able to efficiently 
control the induced infection.  The effect of the phage association with an antibiotic was 
also tested for two of the phages, phi F78E and phi F258E, but the results didn’t 
demonstrate any advantage on this alliance. However, in a subsequent experiment the 
concentration of phi F78E was increased to 109 PFU/ml, it was possible to observe 
effectiveness in reducing the infection effects. Chickens’ mortality decreased in 
average, 25.0 % and morbidity, 41.7 %. Nevertheless, even though results from the 
phages efficiency apparently revealed that low phage concentrations were not effective 
on controlling colibacillosis, experiments performed in APEC naturally infected flocks 
revealed very promising results. The flocks used in these large scale experiments were 
experiencing high mortality rates even after the antibiotic treatment, and a 5×107 
PFU/ml phage cocktail was administered, orally and by spray, in a single dose. The 
mortality rate was controlled to regular levels (≤0.5%) in one week in 46% of the cases, 
in two weeks in 9%, and in three weeks in 36% of the flocks. No recidivism in the 
mortality rate was observed in any flock until slaughter. The gradual decrease in 
mortality might have revealed that the number of chickens that reached acute 
septicaemia and consequently died was diminishing, and that this effect was probably 
due to the phages action, by destroying bacteria on early stages of the APEC infections. 
In the same extent, the probability of bacteria propagation from bird to bird might have 
been prevented. 
The bacteriophage therapy for colibacillosis in poultry 
 
 123  
For these reasons, the lack of efficiency obtained in experimental conditions with E. coli 
challenged chickens, might not necessarily means that phages were not effective in 
destroying the pathogens, but instead that they were not able to control the infection on 
its severe state.  
All these results were presented to the Portuguese Veterinary Authorities (DGV), and 
Controlvet requested permission to launch the product. A provisional authorization was 
conceded until the product is registered. The form required for this process, entitled 
“Application for approval of special use of Veterinary drugs”, is shown in Annex 1. 
Figure VII.1 presents a picture of the phage product named “Colifagos” (A.), as well as 
the information enclosed in the label (written in Portuguese) (B.). This information 
describe the product and its composition, to witch specie and strain it is targeted, the 
therapeutic indications as well as the contraindications, the side effects, the dosage and 
mode of administration, the interactions with other medicines, the safety interval 
between administration and the carcass commercialization, the packaging and the 
advised storing conditions. 
 
 
 
 
 
 
 
 
 
          
                                                      
 
Figure VII.1 A. “Colifagos”: Therapeutic cocktail composed by 3 coliphages directed 
to colibacillosis in poultry. B. Label of the product.  
A.  B. 
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CONCLUDING REMARKS 
 
The planning of this thesis enclosed studies assumed as necessary to the development, 
testing and validation of a therapeutic product constituted by bacteriophages, aiming its 
commercialization.  
On the course of the experiments entailing this main goal, the necessity and will of 
accessing more expeditious techniques and methods was experienced. In fact, it would 
be important to shorten the development period of a phage product for similar 
applications, overcoming the laborious and time consuming phage handling methods. 
Therefore, the development of expeditious techniques, for example to ensure phage 
safety (meaning a strictly lytic phage not encoding toxins) or to assess phage genome 
integrity upon replication, seems to be definitely necessary.   
Relatively to the evaluation of phages as antimicrobials in Veterinary Medicine, it is 
important, firstly, to emphasize that it might not be possible to infer about phage 
efficiency, only by knowing the in vitro hosts lysis rate, or even the phages burst size. It 
is essential to guarantee that the experimental design of in vivo experiments allow 
reaching all the proposed aims. Tests shall be performed preferentially in the target 
animals, and the parameters under study have to be carefully selected, taking in account 
the disease effects in their organisms and the animals’ behavioural alterations. 
Moreover, if, as happened in this study, the researcher is dealing with livestock, 
normally raised in numerous groups and intensive systems, the way of induce the 
infection and its severity must be carefully considered, in order to mimic as faithfully as 
possible the natural occurring disease. It is determinant to the success of the therapy that 
bacteriophages have the opportunity to meet bacteria, before septicemia is installed.  
For the future success of the phage therapy in Veterinary Medicine, there is still much 
work to be undertaken in order to optimise the effectiveness of phages for each kind of 
animal and infection. Much of it was already carried on and all the successes and 
setbacks that have been reported encourage further studies and give confidence to 
believe that, in a near future phages will be currently used in animal production as a 
regular antimicrobial treatment. 
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Figure 1 Application form needed for the approval of special use of Veterinary drugs 
by DGV. 
